苍柏湿毒清治疗支原体性宫颈炎（气虚湿毒证）的临床观察及对小鼠阴道解脲支原体定植干预的免疫机制研究
|
摘要
目的
1观察中药复方苍柏湿毒清治疗支原体性宫颈炎(气虚湿毒证)的临床疗效。
2观察中药复方苍柏湿毒清干预BALB/C小鼠建立阴道感染UU动物模型效果。
3从BALB/c(?)小鼠血IL-2水平、阴道黏膜组织IL-12和LTC4水平、阴道黏膜组织C3b受体表达方面探讨中药复方苍柏湿毒清治疗解脲支原体泌尿生殖道感染的可能免疫调节机制。
方法
本课题研究分两部分进行：
1临床研究
采用随机双盲对照的研究方法,将苍柏湿毒清颗粒和热淋清颗粒加工成外包装一样的制剂统一编盲,入选支原体性宫颈炎(气虚湿毒证)患者按就诊先后顺序随机发药。治疗期间,患者均服用中药颗粒剂每次一袋,每日两次,疗程两周。用药前、用药2周后记录中医证候积分；用药前、用药2周后、停药1周、3周检测阴道pH值、宫颈分泌物白细胞计数、支原体培养,最终以判断疗效,实验结束后统一揭盲。
2实验研究
70只BALB/c(?)小鼠随机分为A1-1组10只、A1-2组10只、B1组10只、A2-1组10只、A2-2组10只、B2组10只、C组10只。
2.1实验一
2.1.1A1-1组、A1-2组经过中药苍柏湿毒清低剂量、高剂量干预7天后,B1组无干预7天后,分别对三组BALB/c小鼠建立阴道感染UU动物模型4周实验结束后取各组小鼠阴道分泌物进行UU培养,计算UU定植成功率,观察中药干预后解脲支原体定植情况。
2.1.2中药苍柏湿毒清对建立阴道感染UU动物模型干预的免疫机制研究。
①采用ELISA法,在实验结束后检测三组BALB/c小鼠血白介素-2(IL-2)值。
②采用ELISA (?)去,在实验结束后检测三组BALB/c小鼠阴道黏膜组织白介素-12(IL-12)和白三烯C4(LTC4)含量。
③采用免疫组织化学技术对三组BALB/c小鼠阴道粘膜C3b受体进行染色,选择有意义的组织相,应用计算机图像处理系统后期处理,每例测5个视野,由计算机计算出所测阳性反应物相对含量的灰度‘值及面积即平均光密度(MOD)。
2.2实验二
2.2.1A2-1组、A2-2组、B2组BALB/c小鼠先建立阴道感染UU动物模型4周,其后A2-1组、A2-2组经过中药苍柏湿毒清低剂量、高剂量干预7天,B2组无中药干预7天,实验结束后取各组小鼠阴道分泌物进行UU培养,计算UU定植成功率,观察中药干预后解脲支原体定植情况。
2.2.2中药苍柏湿毒清对BALB/c小鼠阴道感染UU动物模型干预的免疫机制的研究。
①采用ELISA法,在实验结束后检测三组BALB/c小鼠血IL-2。
②采用ELISA法,在实验结束后检测三组BALB/c小鼠阴道黏膜组织IL-12和LTC4含量。
③采用免疫组织化学技术对三组BALB/c小鼠阴道粘膜C3b受体进行染色,选择有意义的组织相,应用计算机图像处理系统后期处理,每例测5个视野,由计算机计算出所测阳性反应物相对含量的灰度值及面积即平均光密度(MOD)
2.3C组为空白组,不进入实验一、二,实验一、二结束后与其他六组同时取阴道分泌物进行UU培养及各项指标检测。结果
1临床研究
1.1观察支原体性宫颈炎(气虚湿毒证)患者66例,苍柏湿毒清组33例患者中14例痊愈,6例显效,5例进步,8例无效,愈显率60.6%；热淋清组33例患者中8例痊愈,4例显效,6例进步,15例无效,愈显率36.4%。苍柏湿毒清组在治疗支原体性宫颈炎方面愈显率(60.6%)高于热淋清组(36.4%),两组有显著性差异(P<0.05)。苍柏湿毒清组在治疗支原体性宫颈炎(气虚湿毒证)疗效优于热淋清组。
1.2苍柏湿毒清组治疗后患者阴道pH值逐步下降,并趋于正常水平,热淋清组治疗后患者阴道pH值有所下降,并未达到正常值。苍柏湿毒清组在改善阴道pH值方面优于热淋清组。
1.3治疗后,两组患者宫颈分泌物白细胞计数均较治疗前极显著性下降(P<0.01),苍柏湿毒清组治疗后比热淋清组白细胞计数下降更明显。苍柏湿毒清组在降低宫颈分泌物白细胞计数方面优于热淋清组。
1.4治疗后,两组患者中医证候评分较治疗前显著性下降(P<0.05),苍柏湿毒清组比热淋清组下降更明显(P.<0.05)。苍柏湿毒清组在中医证候改善方面优于热淋清组。
2实验研究
2.1UU血清4型致病性
实验二,29只BALB/c小鼠建立阴道感染UU动物模型结束后,对A2-1组、A2-2组、B2组BALB/c小鼠用无菌男用拭子取阴道分泌物,UU培养结果均为阳性,阳性定植率100%,提示UU血清4型可致BALB/c小鼠阴道感染。
2.2成功建立了BALB/c小鼠阴道感染UU的动物模型
对BALB/c小鼠采用颈部皮下注射雌二醇注射液0.2mg,每周一次,共四周；在第二次注射雌二醇注射液(即第二周)后,每天用无菌输液软管向BALB/c小鼠阴道注入预先制备的UU标准株菌液2O μ1(105CCU/ml),连续注入三天；此方法成功建立了BALB/c小鼠阴道感染UU的动物模型。
2.3实验质控条件良好
C组实验入组时、结束时UU阳性率均为0%,提示实验质控条件良好。
2.4UU定植成功率
实验一、二结束时,对A1-1组、A1-2组、B1组、A2-1组、A2-2组、B2组、C组BALB/c小鼠阴道分泌物进行UU培养,UU感染阳性率分别是70.00%(7/10)、66.67%(6/9)、90%(9/10)、66.67%(6/9)、70.00%(7/10)、100%(10/10)、0%(0/10)。
实验一A1-1组、A1-2组小鼠经过苍柏湿毒清干预,部分实验小鼠阴道UU定植阴性。
实验二A2-1组、A2-2组成功建立阴道感染UU的动物模型后,经过苍柏湿毒清干预,部分实验小鼠阴道感染UU转阴。但经统计学分析,六组组间UU阳性定植率比较,统计学上无显著性差异(P>0.05)。
2.5血IL-2
实验一、二结束时,七组BALB/c小鼠血IL-2值由高到低依次是A1-1组(54.16±1.52)、A1-2组(51.86±1.51)、A2-1组(45.33±1.82)、A2-2组(44.45±2.75)、C组(44.02±2.14)、B1组(41.29±1.35)、B2组(35.40±1.78)。
B1组、B2组BALB/c小鼠建立阴道感染UU动物模型血IL-2值低于C组(空白组),统计学上,有显著性差异(P<0.05),提示UU感染后BALB/c小鼠血IL-2值呈低水平
实验一A1-1组、A1-2组小鼠经过苍柏湿毒清干预后再建立动物模型,可提高血IL-2值；统计学上,与C组、B1组均有显著性差异(P<0.05)。提示苍柏湿毒清可提高小鼠血IL-2水平,在防UU感染中发挥重要作用。
实验A2-1组、A2-2组成功建立阴道感染UU的动物模型后经过苍柏湿毒清干预,提示苍柏湿毒清可提高UU感染小鼠血IL-2的低水平,统计学上,与B2组有显著性差异(P<0.05),与C组无显著性差异(P>0.05),在抗UU感染中发挥重要作用。
苍柏湿毒清提高小鼠血IL-2水平,增加TH1细胞,激活或调动体液免疫功能,从而在防UU感染和抗UU感染中发挥重要作用。
2.6阴道黏膜组织IL-12
实验一、二结束时,七组BALB／c小鼠阴道黏膜组织IL-12由高到低依次是B2组(19.37±14.22)、B1组(18.41±13.23)、A2-2组(12.52±3.96)、A2-1组(12.06±4.92)、A1-1组(9.32±2.88)、C组(9.21±5.92)、A1-2组(7.52±3.25)。
B1组、B2组BALB／c小鼠建立阴道感染UU动物模型阴道黏膜组织IL-12值高于C组(空白组),统计学上,有显著性差异(P<0.05),提示UU感染后阴道黏膜组织IL-12值呈高水平。
实验一A1-1组、A1-2组小鼠经过苍柏湿毒清干预后再建立动物模型,可降低阴道黏膜组织IL-12值；统计学上,与B1组有显著性差异(P<0.05),与C组无显著性差异(P>0.05)。提示苍柏湿毒清可降低阴道黏膜组织IL-12水平,在防UU感染中发挥重要作用。
实验二A2-1组、A2-2组成功建立阴道感染UU的动物模型后经过苍柏湿毒清干预,可降低阴道黏膜组织IL-12值,统计学上,与B2组、C组无显著性差异(P>0.05),提示苍柏湿毒清降低UU感染小鼠阴道黏膜组织IL-12的高水平作用不显著。
苍柏湿毒清降低小鼠阴道黏膜组织IL-12水平,在防UU感染中发挥重要作用,在抗UU感染中作用不显著。
2.7阴道黏膜组织LTC4
实验一、二结束时,七组BALB／c小鼠阴道黏膜组织LTC4由高到低依次是B2组(485.61±387.36)、B1组(399.88±297.61)、A2-1组(288.54±113.48)、A2-2组(244.91±52.65)、A1-1组(198.90±54.36)、C组(172.71±75.44)、A1-2组(162.77±66.84)。
B1组、B2组BALB／c(?)小建立阴道感染UU动物模型阴道黏膜组织LTC4值高于C组(空白组),统计学上,有显著性差异(P<0.05),提示UU感染后阴道黏膜组织LTC4值呈高水平。
实验一A1-1组、A1-2组小鼠经过苍柏湿毒清干预后再建立动物模型,可降低阴道黏膜组织LTC4值；统计学上,与B1组有显著性差异(P<0.05),与C组无显著性差异(P>0.05)。提示苍柏湿毒清可降低阴道黏膜组织LTC4水平,在防UU感染中发挥重要作用。
实验二A2-1组、A2-2组成功建立阴道感染UU的动物模型后经过苍柏湿毒清干预,可降低阴道黏膜组织LTC4值,统计学上,与B2组有显著性差异(P<0.05),与C组无显著性差异(P>0.05),提示苍柏湿毒清降低UU感染小鼠阴道黏膜组织LTC4的高水平,在抗UU感染中发挥重要作用。
苍柏湿毒清降低阴道黏膜组织LTC4的水平,可控制血管通透性,减少炎症渗出,保持阴道粘膜屏障完整,可大大减少UU入侵途径,从而在防UU感染和抗UU感染中发挥重要作用。
2.8BALB/c小鼠阴道黏膜组织C3b受体
实验一、二结束时,七组BALB/c小鼠阴道黏膜组织C3b受体平均光密度(MOD),结果：A1-1组(0.038±0.013)、A1-2组(0.045±0.087)、A2-1组(0.039±0.011)、A2-2组(0.042±0.009)、B1组(0.041±0.009)、B2组(0.042±0.012)、C组(0.042±0.010),七组BALB/c(?)小鼠阴道黏膜组织C3b受体平均光密度差异不显著(P>0.05),提示苍柏湿毒清可能不是通过调节C3b受体起到免疫调节作用。
结论
中药复方苍柏湿毒清在治疗支原体性宫颈炎(气虚湿毒证)疗效优于热淋清颗粒,苍柏湿毒清能够有效地降低阴道pH值,并趋向正常,减少宫颈分泌物白细胞计数,以保持局部黏膜完整；中药复方苍柏湿毒清有明显地改善全身及局部症状的作用,具有较强抗支原体的作用。
经过苍柏湿毒清干预,部分实验小鼠阴道uu定植阴性；成功建立阴道感染uu的动物模型后,经过苍柏湿毒清干预,部分实验小鼠阴道感染uu转阴。苍柏湿毒清能够提高小鼠血IL-2,降低小鼠降低阴道黏膜组织IL-12,降低小鼠阴道黏膜组织LTC4,可能不是通过调节小鼠阴道黏膜组织C3b受体起到免疫调节作用,该方在防uu感染和抗uu感染中发挥重要作用。本课题创新点是首次从小鼠血IL-2、阴道黏膜组织IL-12和LTC4、阴道黏膜组织C3b受体水平探讨中药复方苍柏湿毒清在防uu感染和抗uu感染两方面的免疫调节机制。
Objective
1To observe the clinical efficacy of Chinese herbal compound of Cangbaishiduqing (CBSDQ) in treating Mycoplasma cervicitis (the Syndrome of qi deficiency caused by Dampness Dampness toxin).
2To observe the effect of Cangbaishiduqing intervening the establishment of ureaplasma urealyticum model in BALB/c mice.
3To probe the possible immunological regulation mechanism of Cangbaishiduqing intervening ureaplasma urealyticum model in BALB/c mice from IL-2level in serum, IL-12level and LTC4level of vaginal mucosa tissue, the expression of C3b receptors on vaginal mucosa tissue.
Method
The research contains two parts:
I The clinical study
By the study method of randomized double-blind controlled.
Processed the Cangbaishiduqing granules and Relinqing (RLQ) granules into the same outer package and the harmonized compiled blind. Selected patients of mycoplasma cervicitis were randomly dispensing granules by visiting sequence. During the treatment, the patients were taking granules one bag, twice a day in the course of two weeks. Recorded the symptom score before treatment and after two weeks of medication. Detected vaginal pll, count while blood cell (WBC) of cervical secretions, and cultivated mycoplasma before treatment, after two weeks of medication, drug withdrawal one week, three weeks. Determined the efficacyultimately. In the end of study, the blind was exposed.
2The experimental study
Seventy. BALB/c mice were randomly divided into groups A1-1, A1-2, B1, A2-1A2-2, B2and C, ten mice per group.
2.1Experiment I
2.1.1After7days, low dose of Cangbaishiduqing intervening in Group A1-1, high dose intervening in group Al-2, no intervention in group B1, three groups were established ureaplasma urealyticum model. At the end of the experiment, collecting vaginal secretions of each mice were cultivated UU, to observe the effect of Cangbaishiduqing intervention in Ureaplasma urealyticum colonization by calculated the positive rate of UU.
2.1.2Probed the possible immunological regulation mechanism of Cangbaishiduqing intervening the establishment of ureaplasma urealyticum model in BALB/c mice.
①By ELISA, three groups were detected blood Interleukin-2(IL-2) in the end of the experiment.
②By ELISA, three groups were detected the content of interleukin-12(IL-12) and leukotriene C4(LTC4) in vaginal mucosa tissue.
③By immunohistochemistry, C3b receptors on vaginal mucosa tissue were dyed. Chose meaningful images, each case measured5horizons, and calculated the average optical density (MOD) of the positive reaction by application of computer image processing system by computer.
2.2Experiment II
2.2.1First, Group A2-1, Group A2-2, Group B2were established ureaplasma urealyticum model in four weeks. Secondly, low dose of-Cangbaishiduqing was intervening in Group A2-1, high dose intervening in group A2-2, no intervention in group B2for7days. At the end of the experiment, collecting vaginal secretions of each mice were cultivated UU, to observe the effect of Cangbaishiduqing intervention in Ureaplasma urealyticum colonization by calculated the positive rate of UU.
2.2.2Probed the possible immunological regulation mechanism of Cangbaishiduqing treating the establishment of ureaplasma urealyticum model in BALB/c mice
①By ELISA, three groups were detected blood IL-2in the end of the experiment.
②By ELISA, three groups were detected the content of IL-12and LTC4in vaginal mucosa tissue.
③By immunohistochemistry, C3b receptors on vaginal mucosa tissue were dyed. Chose meaningful images, each case measured5horizons, and calculated MOD of the positive reaction by application of computer image processing system by computer.
2.3Group C was the blank group. Group C did not enter the experiment Ⅰ or Ⅱ. At the end of experiment Ⅰ and Ⅱ, collecting vaginal secretions of each mice in group C were cultivated UU with other groups at the same time. Each mouse in group C was detected the same indicators.
Results
1The clinical study
1.166patients were selected. In the33cases of CBSDQ group,14cases were cured,6cases shew effects,5cases had maken progress,8cases shew no effect, the marked recovery rate was60.6%; in the33cases of RLQ group,8cases were cured,4cases shew effects,6cases had maken progress,15cases shew no effect, the marked recovery rate was36.4%. The difference was significant between these two groups (P<0.05). The marked recovery rate of CBSDQ group in the treatment of mycoplasma cervicitis was higher than the rate of RLQ group. The efficacy of CBSDQ was better than the efficacy of RLQ in treatment of mycoplasma cervicitis (the Syndrome of qi deficiency caused by Dampness Dampness toxin).
1.2The vaginal pH value went down to normal gradually in CBSDQ group. The vaginal pH value went down but not to normal in RLQ group. The difference was prominent after and before treated (P<0.05). The vaginal PH value in CBSDQ group decreased more significantly than in RLQ group.
1.3The WBC counts of cervical secretions went down in the two groups. The difference in the WBC counts was prominent after and before treated (P<0.01). The WBC counts in CBSDQ group decreased more significantly (P<0.01) than in RLQ group.
1.4In improving the main symptoms, the difference was prominent (P<0.05) after and before treated in two groups. The syndrome score in CBSDQ group decreased more significantly than in RLQ group.
2The experimental study
2.1The pathogenicity of ureaplasma urealyticum serotype4
In experiment II,29BALB/c mice were successfully established ureaplasma urealyticum model in four weeks. The vaginal secretions of each mouse were cultivated UU all positive (100%). Ureaplasma urealyticum serotype4could cause vaginal infections in BALB/c mice。
2.2Successfully established the ureaplasma urealyticum model of vaginal infections in BALB/c mice
Estrogen-treated female BALB/c mice were inoculated intravaginally by UU serotype4. UU serotype4was successfully inoculated. This method was successfully established the ureaplasma urealyticum model of vaginal infections in BALB/c mice.
2.3Excellent experimental QC conditions.
The positive rate of UU in group C was0%before and after experiment. The experimental QC conditions were excellent.
2.4The success rate of UU colonization
At the end of experiment I and II, the positive rate of UU of vaginal secretions respectively in group A1-1, group A1-2, group B1, group A2-1, group A2-2, group B2was70.00%(7/10),66.67%(6/9),90.00%(9/10),66.67%(6/9),70.00%(7/10),100.00%(10/10)
In experiment I, some mice in group A1-1and group A1-2intervened by Cangbaishiduqing were not successfully established the ureaplasma urealyticum model.
In experiment II, all the mice of group A2-1and group A2-2were successfully established the ureaplasma urealyticum model. After treaded by Cangbaishiduqing, UU was negative in some mice. But the difference of the positive rate of UU was inapparent between groups (P>0.05).
2.5IL-2level in serum
At the end of experiment I and II, the values of IL-2in seven groupse were in descending order:group A1-1(54.16±1.52), group A1-2(51.86±1.51), group A2-1(45.33±1.82), group A2-2(44.45±2.75), group C(44.02±2.14), group B1(41.29±1.35), group B2(35.40±1.78).
The values of IL-2in group B1and group B2were lower than the values in group C. The difference was prominent (P<0.05). The blood IL-2values were in. low level in UU infection of BALB/c mice.
In experiment I, the values of IL-2were raised in group A1-1and group Al-2intervened by Cangbaishiduqing. The values of IL-2in group A1-1and group A1-2had prominent difference with the values in group B1and group C (P<0.05). Cangbaishiduqing played an important role in the prevention of UU infection by raising the serum IL-2levels.
In experiment II, all the mice of group A2-1and group A2-2were successfully established the ureaplasma urcalyticum model. After treaded by Cangbaishiduqing, the values of IL-2were raised in both group A2-1and group A2-2. The values of IL-2in group A2-1and group A2-2had prominent difference with the values in group B2(P<0.05),which had inapparent difference with the values in group C(P>0.05). Cangbaishiduqing played an important role in the anti-UU infection by raising the serum IL-2levels.
Cangbaishiduqing raised the blood IL-2levels in mice, increased TH1cells and activated or mobilized humoral immune function. Cangbaishiduqing played an important role in the prevention of UU infection and the anti-UU infection by raising the serum IL-2levels.
2.61L-12in vaginal mucosa tissue
At the end of experiment I and II, the values of IL-12in seven groups were in descending order:group B2(19.37±14.22), group B1(18.41±13.23), group A2-2(12.52±3.96), group A2-1(12.06±4.92), group A1-1(9.32±2.88), group C (9.21±5.92), group A1-2(7.52±3.25).
The values of IL-12in group B1and group B2were higher than the values in group C. The difference was prominent (P<0.05). The values of IL-12in vaginal mucosa tissue were in high level in UU infection of BALB/c mice.
In experiment I, the values of IL-12were decreased in group A1-1and group A1-2intervened by Cangbaishiduqing. The values of IL-12in group A1-1and group A1-2had prominent difference with the values in group B1(P<0.05), which had inapparent difference with the values in group C(P>0.05). Cangbaishiduqing laycd an important role in the prevention of UU infection by decreasing the IL-12level of vaginal mucosa tissue.
In experiment Ⅱ, all the mice of group A2-1and group A2－2were successfully established the ureaplasma urealyticum model. After treaded by Cangbaishiduqing, the values of IL-12were decreaseed in both group A2-1and group A2-2. The values of IL-12in group A2-1and group A2-2had inapparent difference with the values in group B2and group C (P>0.05). Cangbaishiduqing decreasing the IL-12high level was not significant.
Cangbaishiduqing decreased the IL-12level of vaginal mucosa tissue in mice. Cangbaishiduqing played an important role in the prevention of UU infection by decreasing the serum IL－2. Cangbaishiduqing played an unimportant role in the anti-UU infection.
2.7LTC4in vaginal mucosa tissue
At the end of experiment I and Ⅱ, the values of LTC4in seven groups were in descending order:group B2(485.61±387.36), group B1(399.88±297.61), group A2-1(288.54±113.48), group A2-2(244.91±52.65), group Al-1(198.90±54.36), group C (172.71±75.44), group A1-2(162.77±66.84).
The values of LTC4in group B1and group B2were higher than the values in group C. The difference was prominent(P<0.05). The values of LTC4in vaginal mucosa tissue were in high level in UU infection of BALB/c mice.
In experiment I, the values of LTC4were decreased in group A1-1and group A1-2intervened by Cangbaishiduqing. The values of LTC4in group A1-1and group A1-2had prominent difference with the values in group B1(P<0.05), which had inapparent difference with the values in group C(P>0.05). Cangbaishiduqing played an important role in the prevention of UU infection by decreasing the LTC4level of vaginal mucosa tissue.
In experiment Ⅱ, all the mice of group A2-1and group A2-2were successfully established the ureaplasma urealyticum model. After treaded by Cangba i sh i duq i ng, the values of LTC4decreaseed in both group A2-1and group A2-2. The values of LTC4in group A2-1and group A2－2had prominent difference with the values in group B1(P<0.05), which had inapparent difference with the values in group C (P>0.05). Cangbaishiduqing played an important role in the anti-UU infection by decreasing the LTC4level of of vaginal mucosa tissue.
'Cangbaishiduqing decreased the'LTC4level of vaginal mucosa'tissu'e in mice, controled vascular permeability, reduced inflammatory exudate, kept the integrity of vaginal mucous membrane barrier in order to greatly reduce the UU invasion.Cangbaishiduqing played an important role in the prevention of UU infection and the anti-UU infection by decreasing the LTC4level.
2.8The expression of C3b receptors on vaginal mucosa tissue
At the end of ex·periment I and Ⅱ, the MOD of C3b receptors in seven groups were espectively:group A1-1(0.038±0.013), group Al－2(0.045±0.087), group A2-1(0.039±0.011), group A2-2(0.042±0.009), group B1(0.041±0.009), group B2(0.042±0.012), group C (0.042±0.010). The difference in seven groups was inapparent(P>0.05). Cangbaishiduqing might not play an immunomodulatory effects by regulating C3b receptors.
Conclusions
The efficacy of Cangbaishiduqing was better than the efficacy of Relinqing in treatment of mycoplasma cervicitis(the syndrome of qi deficiency caused by dampness toxin). Cangbaishiduqing could effectively decrease the vaginal pH value to normal levels and could decrease the WBC counts in order to keep the integrity of vaginal mucous membrane barrier. Cangbaishiduqing could significantly improve the systemic and local symptoms. Cangbaishiduqing played a strong role of anti-mycoplasma.
By Cangbaishiduqing intervening, some mice were not successfully established the ureaplasma urealyticum model. Successfully established the ureaplasma urealyticum model after treaded by Cangbaishiduqing, UU was negative in some mice. Cangbaishiduqing could raise the blood I L-2level, decrease the IL-12level and the LTC4level of vaginal mucosa tissue, and might not play an immunomodulatory effects by regulating C3b receptors. Cangbaishiduqing played an important role in the prevention of UU infection and in the anti-UU infection. The innovation of this project, containing firstly the blood IL-2level, the IL-12level and the LTC4level of vaginal mucosa tissue, regulating C3b receptor,was to explore the mechanism of herbal compound from the prevention of UU infection and the anti-UU infection.
1观察中药复方苍柏湿毒清治疗支原体性宫颈炎(气虚湿毒证)的临床疗效。
2观察中药复方苍柏湿毒清干预BALB/C小鼠建立阴道感染UU动物模型效果。
3从BALB/c(?)小鼠血IL-2水平、阴道黏膜组织IL-12和LTC4水平、阴道黏膜组织C3b受体表达方面探讨中药复方苍柏湿毒清治疗解脲支原体泌尿生殖道感染的可能免疫调节机制。
方法
本课题研究分两部分进行：
1临床研究
采用随机双盲对照的研究方法,将苍柏湿毒清颗粒和热淋清颗粒加工成外包装一样的制剂统一编盲,入选支原体性宫颈炎(气虚湿毒证)患者按就诊先后顺序随机发药。治疗期间,患者均服用中药颗粒剂每次一袋,每日两次,疗程两周。用药前、用药2周后记录中医证候积分；用药前、用药2周后、停药1周、3周检测阴道pH值、宫颈分泌物白细胞计数、支原体培养,最终以判断疗效,实验结束后统一揭盲。
2实验研究
70只BALB/c(?)小鼠随机分为A1-1组10只、A1-2组10只、B1组10只、A2-1组10只、A2-2组10只、B2组10只、C组10只。
2.1实验一
2.1.1A1-1组、A1-2组经过中药苍柏湿毒清低剂量、高剂量干预7天后,B1组无干预7天后,分别对三组BALB/c小鼠建立阴道感染UU动物模型4周实验结束后取各组小鼠阴道分泌物进行UU培养,计算UU定植成功率,观察中药干预后解脲支原体定植情况。
2.1.2中药苍柏湿毒清对建立阴道感染UU动物模型干预的免疫机制研究。
①采用ELISA法,在实验结束后检测三组BALB/c小鼠血白介素-2(IL-2)值。
②采用ELISA (?)去,在实验结束后检测三组BALB/c小鼠阴道黏膜组织白介素-12(IL-12)和白三烯C4(LTC4)含量。
③采用免疫组织化学技术对三组BALB/c小鼠阴道粘膜C3b受体进行染色,选择有意义的组织相,应用计算机图像处理系统后期处理,每例测5个视野,由计算机计算出所测阳性反应物相对含量的灰度‘值及面积即平均光密度(MOD)。
2.2实验二
2.2.1A2-1组、A2-2组、B2组BALB/c小鼠先建立阴道感染UU动物模型4周,其后A2-1组、A2-2组经过中药苍柏湿毒清低剂量、高剂量干预7天,B2组无中药干预7天,实验结束后取各组小鼠阴道分泌物进行UU培养,计算UU定植成功率,观察中药干预后解脲支原体定植情况。
2.2.2中药苍柏湿毒清对BALB/c小鼠阴道感染UU动物模型干预的免疫机制的研究。
①采用ELISA法,在实验结束后检测三组BALB/c小鼠血IL-2。
②采用ELISA法,在实验结束后检测三组BALB/c小鼠阴道黏膜组织IL-12和LTC4含量。
③采用免疫组织化学技术对三组BALB/c小鼠阴道粘膜C3b受体进行染色,选择有意义的组织相,应用计算机图像处理系统后期处理,每例测5个视野,由计算机计算出所测阳性反应物相对含量的灰度值及面积即平均光密度(MOD)
2.3C组为空白组,不进入实验一、二,实验一、二结束后与其他六组同时取阴道分泌物进行UU培养及各项指标检测。结果
1临床研究
1.1观察支原体性宫颈炎(气虚湿毒证)患者66例,苍柏湿毒清组33例患者中14例痊愈,6例显效,5例进步,8例无效,愈显率60.6%；热淋清组33例患者中8例痊愈,4例显效,6例进步,15例无效,愈显率36.4%。苍柏湿毒清组在治疗支原体性宫颈炎方面愈显率(60.6%)高于热淋清组(36.4%),两组有显著性差异(P<0.05)。苍柏湿毒清组在治疗支原体性宫颈炎(气虚湿毒证)疗效优于热淋清组。
1.2苍柏湿毒清组治疗后患者阴道pH值逐步下降,并趋于正常水平,热淋清组治疗后患者阴道pH值有所下降,并未达到正常值。苍柏湿毒清组在改善阴道pH值方面优于热淋清组。
1.3治疗后,两组患者宫颈分泌物白细胞计数均较治疗前极显著性下降(P<0.01),苍柏湿毒清组治疗后比热淋清组白细胞计数下降更明显。苍柏湿毒清组在降低宫颈分泌物白细胞计数方面优于热淋清组。
1.4治疗后,两组患者中医证候评分较治疗前显著性下降(P<0.05),苍柏湿毒清组比热淋清组下降更明显(P.<0.05)。苍柏湿毒清组在中医证候改善方面优于热淋清组。
2实验研究
2.1UU血清4型致病性
实验二,29只BALB/c小鼠建立阴道感染UU动物模型结束后,对A2-1组、A2-2组、B2组BALB/c小鼠用无菌男用拭子取阴道分泌物,UU培养结果均为阳性,阳性定植率100%,提示UU血清4型可致BALB/c小鼠阴道感染。
2.2成功建立了BALB/c小鼠阴道感染UU的动物模型
对BALB/c小鼠采用颈部皮下注射雌二醇注射液0.2mg,每周一次,共四周；在第二次注射雌二醇注射液(即第二周)后,每天用无菌输液软管向BALB/c小鼠阴道注入预先制备的UU标准株菌液2O μ1(105CCU/ml),连续注入三天；此方法成功建立了BALB/c小鼠阴道感染UU的动物模型。
2.3实验质控条件良好
C组实验入组时、结束时UU阳性率均为0%,提示实验质控条件良好。
2.4UU定植成功率
实验一、二结束时,对A1-1组、A1-2组、B1组、A2-1组、A2-2组、B2组、C组BALB/c小鼠阴道分泌物进行UU培养,UU感染阳性率分别是70.00%(7/10)、66.67%(6/9)、90%(9/10)、66.67%(6/9)、70.00%(7/10)、100%(10/10)、0%(0/10)。
实验一A1-1组、A1-2组小鼠经过苍柏湿毒清干预,部分实验小鼠阴道UU定植阴性。
实验二A2-1组、A2-2组成功建立阴道感染UU的动物模型后,经过苍柏湿毒清干预,部分实验小鼠阴道感染UU转阴。但经统计学分析,六组组间UU阳性定植率比较,统计学上无显著性差异(P>0.05)。
2.5血IL-2
实验一、二结束时,七组BALB/c小鼠血IL-2值由高到低依次是A1-1组(54.16±1.52)、A1-2组(51.86±1.51)、A2-1组(45.33±1.82)、A2-2组(44.45±2.75)、C组(44.02±2.14)、B1组(41.29±1.35)、B2组(35.40±1.78)。
B1组、B2组BALB/c小鼠建立阴道感染UU动物模型血IL-2值低于C组(空白组),统计学上,有显著性差异(P<0.05),提示UU感染后BALB/c小鼠血IL-2值呈低水平
实验一A1-1组、A1-2组小鼠经过苍柏湿毒清干预后再建立动物模型,可提高血IL-2值；统计学上,与C组、B1组均有显著性差异(P<0.05)。提示苍柏湿毒清可提高小鼠血IL-2水平,在防UU感染中发挥重要作用。
实验A2-1组、A2-2组成功建立阴道感染UU的动物模型后经过苍柏湿毒清干预,提示苍柏湿毒清可提高UU感染小鼠血IL-2的低水平,统计学上,与B2组有显著性差异(P<0.05),与C组无显著性差异(P>0.05),在抗UU感染中发挥重要作用。
苍柏湿毒清提高小鼠血IL-2水平,增加TH1细胞,激活或调动体液免疫功能,从而在防UU感染和抗UU感染中发挥重要作用。
2.6阴道黏膜组织IL-12
实验一、二结束时,七组BALB／c小鼠阴道黏膜组织IL-12由高到低依次是B2组(19.37±14.22)、B1组(18.41±13.23)、A2-2组(12.52±3.96)、A2-1组(12.06±4.92)、A1-1组(9.32±2.88)、C组(9.21±5.92)、A1-2组(7.52±3.25)。
B1组、B2组BALB／c小鼠建立阴道感染UU动物模型阴道黏膜组织IL-12值高于C组(空白组),统计学上,有显著性差异(P<0.05),提示UU感染后阴道黏膜组织IL-12值呈高水平。
实验一A1-1组、A1-2组小鼠经过苍柏湿毒清干预后再建立动物模型,可降低阴道黏膜组织IL-12值；统计学上,与B1组有显著性差异(P<0.05),与C组无显著性差异(P>0.05)。提示苍柏湿毒清可降低阴道黏膜组织IL-12水平,在防UU感染中发挥重要作用。
实验二A2-1组、A2-2组成功建立阴道感染UU的动物模型后经过苍柏湿毒清干预,可降低阴道黏膜组织IL-12值,统计学上,与B2组、C组无显著性差异(P>0.05),提示苍柏湿毒清降低UU感染小鼠阴道黏膜组织IL-12的高水平作用不显著。
苍柏湿毒清降低小鼠阴道黏膜组织IL-12水平,在防UU感染中发挥重要作用,在抗UU感染中作用不显著。
2.7阴道黏膜组织LTC4
实验一、二结束时,七组BALB／c小鼠阴道黏膜组织LTC4由高到低依次是B2组(485.61±387.36)、B1组(399.88±297.61)、A2-1组(288.54±113.48)、A2-2组(244.91±52.65)、A1-1组(198.90±54.36)、C组(172.71±75.44)、A1-2组(162.77±66.84)。
B1组、B2组BALB／c(?)小建立阴道感染UU动物模型阴道黏膜组织LTC4值高于C组(空白组),统计学上,有显著性差异(P<0.05),提示UU感染后阴道黏膜组织LTC4值呈高水平。
实验一A1-1组、A1-2组小鼠经过苍柏湿毒清干预后再建立动物模型,可降低阴道黏膜组织LTC4值；统计学上,与B1组有显著性差异(P<0.05),与C组无显著性差异(P>0.05)。提示苍柏湿毒清可降低阴道黏膜组织LTC4水平,在防UU感染中发挥重要作用。
实验二A2-1组、A2-2组成功建立阴道感染UU的动物模型后经过苍柏湿毒清干预,可降低阴道黏膜组织LTC4值,统计学上,与B2组有显著性差异(P<0.05),与C组无显著性差异(P>0.05),提示苍柏湿毒清降低UU感染小鼠阴道黏膜组织LTC4的高水平,在抗UU感染中发挥重要作用。
苍柏湿毒清降低阴道黏膜组织LTC4的水平,可控制血管通透性,减少炎症渗出,保持阴道粘膜屏障完整,可大大减少UU入侵途径,从而在防UU感染和抗UU感染中发挥重要作用。
2.8BALB/c小鼠阴道黏膜组织C3b受体
实验一、二结束时,七组BALB/c小鼠阴道黏膜组织C3b受体平均光密度(MOD),结果：A1-1组(0.038±0.013)、A1-2组(0.045±0.087)、A2-1组(0.039±0.011)、A2-2组(0.042±0.009)、B1组(0.041±0.009)、B2组(0.042±0.012)、C组(0.042±0.010),七组BALB/c(?)小鼠阴道黏膜组织C3b受体平均光密度差异不显著(P>0.05),提示苍柏湿毒清可能不是通过调节C3b受体起到免疫调节作用。
结论
中药复方苍柏湿毒清在治疗支原体性宫颈炎(气虚湿毒证)疗效优于热淋清颗粒,苍柏湿毒清能够有效地降低阴道pH值,并趋向正常,减少宫颈分泌物白细胞计数,以保持局部黏膜完整；中药复方苍柏湿毒清有明显地改善全身及局部症状的作用,具有较强抗支原体的作用。
经过苍柏湿毒清干预,部分实验小鼠阴道uu定植阴性；成功建立阴道感染uu的动物模型后,经过苍柏湿毒清干预,部分实验小鼠阴道感染uu转阴。苍柏湿毒清能够提高小鼠血IL-2,降低小鼠降低阴道黏膜组织IL-12,降低小鼠阴道黏膜组织LTC4,可能不是通过调节小鼠阴道黏膜组织C3b受体起到免疫调节作用,该方在防uu感染和抗uu感染中发挥重要作用。本课题创新点是首次从小鼠血IL-2、阴道黏膜组织IL-12和LTC4、阴道黏膜组织C3b受体水平探讨中药复方苍柏湿毒清在防uu感染和抗uu感染两方面的免疫调节机制。
Objective
1To observe the clinical efficacy of Chinese herbal compound of Cangbaishiduqing (CBSDQ) in treating Mycoplasma cervicitis (the Syndrome of qi deficiency caused by Dampness Dampness toxin).
2To observe the effect of Cangbaishiduqing intervening the establishment of ureaplasma urealyticum model in BALB/c mice.
3To probe the possible immunological regulation mechanism of Cangbaishiduqing intervening ureaplasma urealyticum model in BALB/c mice from IL-2level in serum, IL-12level and LTC4level of vaginal mucosa tissue, the expression of C3b receptors on vaginal mucosa tissue.
Method
The research contains two parts:
I The clinical study
By the study method of randomized double-blind controlled.
Processed the Cangbaishiduqing granules and Relinqing (RLQ) granules into the same outer package and the harmonized compiled blind. Selected patients of mycoplasma cervicitis were randomly dispensing granules by visiting sequence. During the treatment, the patients were taking granules one bag, twice a day in the course of two weeks. Recorded the symptom score before treatment and after two weeks of medication. Detected vaginal pll, count while blood cell (WBC) of cervical secretions, and cultivated mycoplasma before treatment, after two weeks of medication, drug withdrawal one week, three weeks. Determined the efficacyultimately. In the end of study, the blind was exposed.
2The experimental study
Seventy. BALB/c mice were randomly divided into groups A1-1, A1-2, B1, A2-1A2-2, B2and C, ten mice per group.
2.1Experiment I
2.1.1After7days, low dose of Cangbaishiduqing intervening in Group A1-1, high dose intervening in group Al-2, no intervention in group B1, three groups were established ureaplasma urealyticum model. At the end of the experiment, collecting vaginal secretions of each mice were cultivated UU, to observe the effect of Cangbaishiduqing intervention in Ureaplasma urealyticum colonization by calculated the positive rate of UU.
2.1.2Probed the possible immunological regulation mechanism of Cangbaishiduqing intervening the establishment of ureaplasma urealyticum model in BALB/c mice.
①By ELISA, three groups were detected blood Interleukin-2(IL-2) in the end of the experiment.
②By ELISA, three groups were detected the content of interleukin-12(IL-12) and leukotriene C4(LTC4) in vaginal mucosa tissue.
③By immunohistochemistry, C3b receptors on vaginal mucosa tissue were dyed. Chose meaningful images, each case measured5horizons, and calculated the average optical density (MOD) of the positive reaction by application of computer image processing system by computer.
2.2Experiment II
2.2.1First, Group A2-1, Group A2-2, Group B2were established ureaplasma urealyticum model in four weeks. Secondly, low dose of-Cangbaishiduqing was intervening in Group A2-1, high dose intervening in group A2-2, no intervention in group B2for7days. At the end of the experiment, collecting vaginal secretions of each mice were cultivated UU, to observe the effect of Cangbaishiduqing intervention in Ureaplasma urealyticum colonization by calculated the positive rate of UU.
2.2.2Probed the possible immunological regulation mechanism of Cangbaishiduqing treating the establishment of ureaplasma urealyticum model in BALB/c mice
①By ELISA, three groups were detected blood IL-2in the end of the experiment.
②By ELISA, three groups were detected the content of IL-12and LTC4in vaginal mucosa tissue.
③By immunohistochemistry, C3b receptors on vaginal mucosa tissue were dyed. Chose meaningful images, each case measured5horizons, and calculated MOD of the positive reaction by application of computer image processing system by computer.
2.3Group C was the blank group. Group C did not enter the experiment Ⅰ or Ⅱ. At the end of experiment Ⅰ and Ⅱ, collecting vaginal secretions of each mice in group C were cultivated UU with other groups at the same time. Each mouse in group C was detected the same indicators.
Results
1The clinical study
1.166patients were selected. In the33cases of CBSDQ group,14cases were cured,6cases shew effects,5cases had maken progress,8cases shew no effect, the marked recovery rate was60.6%; in the33cases of RLQ group,8cases were cured,4cases shew effects,6cases had maken progress,15cases shew no effect, the marked recovery rate was36.4%. The difference was significant between these two groups (P<0.05). The marked recovery rate of CBSDQ group in the treatment of mycoplasma cervicitis was higher than the rate of RLQ group. The efficacy of CBSDQ was better than the efficacy of RLQ in treatment of mycoplasma cervicitis (the Syndrome of qi deficiency caused by Dampness Dampness toxin).
1.2The vaginal pH value went down to normal gradually in CBSDQ group. The vaginal pH value went down but not to normal in RLQ group. The difference was prominent after and before treated (P<0.05). The vaginal PH value in CBSDQ group decreased more significantly than in RLQ group.
1.3The WBC counts of cervical secretions went down in the two groups. The difference in the WBC counts was prominent after and before treated (P<0.01). The WBC counts in CBSDQ group decreased more significantly (P<0.01) than in RLQ group.
1.4In improving the main symptoms, the difference was prominent (P<0.05) after and before treated in two groups. The syndrome score in CBSDQ group decreased more significantly than in RLQ group.
2The experimental study
2.1The pathogenicity of ureaplasma urealyticum serotype4
In experiment II,29BALB/c mice were successfully established ureaplasma urealyticum model in four weeks. The vaginal secretions of each mouse were cultivated UU all positive (100%). Ureaplasma urealyticum serotype4could cause vaginal infections in BALB/c mice。
2.2Successfully established the ureaplasma urealyticum model of vaginal infections in BALB/c mice
Estrogen-treated female BALB/c mice were inoculated intravaginally by UU serotype4. UU serotype4was successfully inoculated. This method was successfully established the ureaplasma urealyticum model of vaginal infections in BALB/c mice.
2.3Excellent experimental QC conditions.
The positive rate of UU in group C was0%before and after experiment. The experimental QC conditions were excellent.
2.4The success rate of UU colonization
At the end of experiment I and II, the positive rate of UU of vaginal secretions respectively in group A1-1, group A1-2, group B1, group A2-1, group A2-2, group B2was70.00%(7/10),66.67%(6/9),90.00%(9/10),66.67%(6/9),70.00%(7/10),100.00%(10/10)
In experiment I, some mice in group A1-1and group A1-2intervened by Cangbaishiduqing were not successfully established the ureaplasma urealyticum model.
In experiment II, all the mice of group A2-1and group A2-2were successfully established the ureaplasma urealyticum model. After treaded by Cangbaishiduqing, UU was negative in some mice. But the difference of the positive rate of UU was inapparent between groups (P>0.05).
2.5IL-2level in serum
At the end of experiment I and II, the values of IL-2in seven groupse were in descending order:group A1-1(54.16±1.52), group A1-2(51.86±1.51), group A2-1(45.33±1.82), group A2-2(44.45±2.75), group C(44.02±2.14), group B1(41.29±1.35), group B2(35.40±1.78).
The values of IL-2in group B1and group B2were lower than the values in group C. The difference was prominent (P<0.05). The blood IL-2values were in. low level in UU infection of BALB/c mice.
In experiment I, the values of IL-2were raised in group A1-1and group Al-2intervened by Cangbaishiduqing. The values of IL-2in group A1-1and group A1-2had prominent difference with the values in group B1and group C (P<0.05). Cangbaishiduqing played an important role in the prevention of UU infection by raising the serum IL-2levels.
In experiment II, all the mice of group A2-1and group A2-2were successfully established the ureaplasma urcalyticum model. After treaded by Cangbaishiduqing, the values of IL-2were raised in both group A2-1and group A2-2. The values of IL-2in group A2-1and group A2-2had prominent difference with the values in group B2(P<0.05),which had inapparent difference with the values in group C(P>0.05). Cangbaishiduqing played an important role in the anti-UU infection by raising the serum IL-2levels.
Cangbaishiduqing raised the blood IL-2levels in mice, increased TH1cells and activated or mobilized humoral immune function. Cangbaishiduqing played an important role in the prevention of UU infection and the anti-UU infection by raising the serum IL-2levels.
2.61L-12in vaginal mucosa tissue
At the end of experiment I and II, the values of IL-12in seven groups were in descending order:group B2(19.37±14.22), group B1(18.41±13.23), group A2-2(12.52±3.96), group A2-1(12.06±4.92), group A1-1(9.32±2.88), group C (9.21±5.92), group A1-2(7.52±3.25).
The values of IL-12in group B1and group B2were higher than the values in group C. The difference was prominent (P<0.05). The values of IL-12in vaginal mucosa tissue were in high level in UU infection of BALB/c mice.
In experiment I, the values of IL-12were decreased in group A1-1and group A1-2intervened by Cangbaishiduqing. The values of IL-12in group A1-1and group A1-2had prominent difference with the values in group B1(P<0.05), which had inapparent difference with the values in group C(P>0.05). Cangbaishiduqing laycd an important role in the prevention of UU infection by decreasing the IL-12level of vaginal mucosa tissue.
In experiment Ⅱ, all the mice of group A2-1and group A2－2were successfully established the ureaplasma urealyticum model. After treaded by Cangbaishiduqing, the values of IL-12were decreaseed in both group A2-1and group A2-2. The values of IL-12in group A2-1and group A2-2had inapparent difference with the values in group B2and group C (P>0.05). Cangbaishiduqing decreasing the IL-12high level was not significant.
Cangbaishiduqing decreased the IL-12level of vaginal mucosa tissue in mice. Cangbaishiduqing played an important role in the prevention of UU infection by decreasing the serum IL－2. Cangbaishiduqing played an unimportant role in the anti-UU infection.
2.7LTC4in vaginal mucosa tissue
At the end of experiment I and Ⅱ, the values of LTC4in seven groups were in descending order:group B2(485.61±387.36), group B1(399.88±297.61), group A2-1(288.54±113.48), group A2-2(244.91±52.65), group Al-1(198.90±54.36), group C (172.71±75.44), group A1-2(162.77±66.84).
The values of LTC4in group B1and group B2were higher than the values in group C. The difference was prominent(P<0.05). The values of LTC4in vaginal mucosa tissue were in high level in UU infection of BALB/c mice.
In experiment I, the values of LTC4were decreased in group A1-1and group A1-2intervened by Cangbaishiduqing. The values of LTC4in group A1-1and group A1-2had prominent difference with the values in group B1(P<0.05), which had inapparent difference with the values in group C(P>0.05). Cangbaishiduqing played an important role in the prevention of UU infection by decreasing the LTC4level of vaginal mucosa tissue.
In experiment Ⅱ, all the mice of group A2-1and group A2-2were successfully established the ureaplasma urealyticum model. After treaded by Cangba i sh i duq i ng, the values of LTC4decreaseed in both group A2-1and group A2-2. The values of LTC4in group A2-1and group A2－2had prominent difference with the values in group B1(P<0.05), which had inapparent difference with the values in group C (P>0.05). Cangbaishiduqing played an important role in the anti-UU infection by decreasing the LTC4level of of vaginal mucosa tissue.
'Cangbaishiduqing decreased the'LTC4level of vaginal mucosa'tissu'e in mice, controled vascular permeability, reduced inflammatory exudate, kept the integrity of vaginal mucous membrane barrier in order to greatly reduce the UU invasion.Cangbaishiduqing played an important role in the prevention of UU infection and the anti-UU infection by decreasing the LTC4level.
2.8The expression of C3b receptors on vaginal mucosa tissue
At the end of ex·periment I and Ⅱ, the MOD of C3b receptors in seven groups were espectively:group A1-1(0.038±0.013), group Al－2(0.045±0.087), group A2-1(0.039±0.011), group A2-2(0.042±0.009), group B1(0.041±0.009), group B2(0.042±0.012), group C (0.042±0.010). The difference in seven groups was inapparent(P>0.05). Cangbaishiduqing might not play an immunomodulatory effects by regulating C3b receptors.
Conclusions
The efficacy of Cangbaishiduqing was better than the efficacy of Relinqing in treatment of mycoplasma cervicitis(the syndrome of qi deficiency caused by dampness toxin). Cangbaishiduqing could effectively decrease the vaginal pH value to normal levels and could decrease the WBC counts in order to keep the integrity of vaginal mucous membrane barrier. Cangbaishiduqing could significantly improve the systemic and local symptoms. Cangbaishiduqing played a strong role of anti-mycoplasma.
By Cangbaishiduqing intervening, some mice were not successfully established the ureaplasma urealyticum model. Successfully established the ureaplasma urealyticum model after treaded by Cangbaishiduqing, UU was negative in some mice. Cangbaishiduqing could raise the blood I L-2level, decrease the IL-12level and the LTC4level of vaginal mucosa tissue, and might not play an immunomodulatory effects by regulating C3b receptors. Cangbaishiduqing played an important role in the prevention of UU infection and in the anti-UU infection. The innovation of this project, containing firstly the blood IL-2level, the IL-12level and the LTC4level of vaginal mucosa tissue, regulating C3b receptor,was to explore the mechanism of herbal compound from the prevention of UU infection and the anti-UU infection.
引文
[1]石慧.龙胆泻肝汤联合阿奇霉素阴道上药治疗女性生殖道解脲支原体感染[D].湖北：湖北中医药大学,2012.
[2]薛连才.黄连解毒汤加味在解脲支原体感染患者中的应用[J].中国药物与临床,2012,12(增刊)：81.
[3]雷林,赵荣.中药内服外用治疗女性解脲支原体、沙眼衣原体感染36例疗效观察[J].天津中医药,2007,24(1)：32.
[4]徐东杰.康乐宁治疗女性泌尿生殖道解脉支原体感染的临床观察及研究[D].长春：长春中医药大学,2007.
[5]杨小芳.中西医联合治疗支原体衣原体生殖道感染[J].中华中医药学刊,2007,25(4)：850-851.
[6]陈启显,陈劝显.中西医结合治疗非淋菌性尿道炎36例疗效观察[J].实用中西医结合临床,2006,6(1)：35.
[7]邢燕军.复方利康液外用治疗解脲支原体性阴道炎的临床疗效观察[J].中国实验方剂学杂志,2003,9(4)：64.
[8]冯光荣,张娜.加味五味消毒饮联合阿奇霉素治疗解脲支原体阳性宫颈炎30例疗效观察[J].河南中医,2008,28(9)：46-47.
[9]夏如意,谈珍瑜,刘文娥.盆炎丸治疗多重耐药解脲支原体感染的临床观察[J].湖南中医药大学学报,2012,32(3)：53-55,67.
[10]宋春花,常欣峰,韩立民.带下病中医辨证分型与解脲支原体感染的关系[J].赣南医学院学报,2010,30(2)：260.
[11]陈旭.梁学林教授治疗耐药性解脲支原体感染及继发不孕症经验[J].中华中医药学刊,2007,25(6)：1116-1117.
[12]韦红,陈琢,徐萍.洁泽Ⅰ号抗解脲支原体药效实验及其对解脲支原体宫颈炎的治疗作用[J].华中科技大学学报(医学版),2007,36(1)：87-90.
[13]李元文,孙占学,张丰川.中药苍柏湿毒清颗粒剂对解脲支原体体外作用的实验研究[J].中国性科学,2008,17(10)：10-12、17.
[14]陈少芳,叶敦敏.中西医结合治疗女性解脲支原体生殖道感染50例[J].新中医,2006,38(8)：78.
[15]任光荣.《傅青主女科》带下五方的学习应用体会[J].甘肃中医,2008,21(11)：2-4.
[16]张志礼.中西医结合皮肤性病学[M].北京：人民卫生出版社,2000：380-383.
[17]吴英男.辨证治疗非淋菌性尿道炎106例[J].实用中医内科杂志,2002,16(1)：43.
[18]丁原全,马乾章.中医辨证与支原体感染浅析[J].辽宁中医杂志,2002,29(12)：716.
[19]李元文,张丰川.性病防治420问[M].北京：中国中医药出版社,2005：159-161.
[20]陈旭.梁学林教授治疗耐药性解脲支原体感染及继发不孕症经验[J].中华中医药学刊,2007,25(6)：1115-1116.
[21]樊庆华,谢争,丁辉.中药用于泌尿生殖系统支原体感染并抗生素耐药病例疗效评估[J].中国妇幼保健,2006,21(5)：710-711.
[22]孙跃农,胡莺,林雯.中医药治疗解脉支原体感染所致滑胎48例临床观察[J].云南中医中药杂志,2007,28(11)：17-18.
[23]毛惠,戴晓蓉,詹平.中药内服外洗治疗妊娠中晚期解脲支原体感染60例[J].中国中西医结合杂志,2006,07(5)：89.
[24]张立春,田成海,梁丽丽.黄连粉治疗解脲支原体阴道炎60例疗效观察[J].长春中医药大学学报,2011,27(6)：1024.
[25]邢燕军.复方利康液外用治疗解脲支原体性阴道炎的临床疗效观察[J].中国实验方剂学杂志,2003,9(4)：64.
[26]田虹利,冯洪声,张淑杰.黄鹤止痒方治疗支原体阴道炎80例[J].陕西中医,2009,30(11)：1462.
[27]李海,邱曙光.阴道微波联合中药冲洗治疗女性解脉支原体感染80例临床观察[J].中国性科学,2008,17(9)：21-22.
[28]梁文丽,杨志新,谢爱香.联合用药治疗女性生殖道支原体感染30例[J].中国中医药现代远程教育,2011,10(01)：141-142.
[29]李艳莎,张新.中西医结合治疗泌尿生殖道支原体感染的临床用药体会[J].中医临床研究,2012,4(12)：11-12.
[30]石慧,谢靳.胆泻肝汤联合阿奇霉素阴道给药治疗女性生殖道解脲支原体感染[J].中西医结合研究,2012,4(1)：1-3.
[31]王雪鹤,樊希芬,郝建波.夕腥草外用联合克拉霉素治疗生殖道解脲支原体感染 138例[J].青岛医药卫生,2005,37(3)：180.
[32]王薇华,刘格,叶花.中西医结合外治法治疗耐药性解脲支原体感染33例临床观察[J].中医药导报,2012,18(7)：41-42.
[33]张颖纯.外用加味四黄洗剂治疗女性解脲支原体感染阴道(宫颈)炎的临床研究[D].北京：北京中医药大学,2012.
[34]赵剑英.中西医结合治疗解脉支原体泌尿生殖道感染[J].浙江中西医结合杂志,2007,17(5)：308-309.
[35]朱习平,高思娥,钱纪银.中西医联合治疗女性生殖道解脉支原体感染的疗效观察[J].中国医药指南,2007,5(10)：171-172.
[36]杨小芳.中西医联合治疗支原体衣原体生殖道感染[J].中华中医药学刊,2007,25(4)：850-851.
[37]邓卫红.中西医结合治疗支原体、衣原体生殖道感染疗效观察[J].中国中医急症,2009,18(3)：372-373.
[38]吴庆四,朱长太,徐东芳等.中药对解脲支原体临床分离株的体外抑制试验研究[J].安徽医药,2006,10(5)：332-333.
[39]董海艳,周丽萍,王乐丹.3味中药对解脲支原体体外抑制作用的实验研究[J].现代中西医结合杂志,2004,13(21)：2824、2827.
[40]廖镜云,郭汉香.解脲支原体中药药敏试验[J].江西中医学院学报,2006,18(3)：56-57.
[41]田正阳,丁原全,梁学林.中药抗解脲支原体的药敏试验[J].辽宁中医杂志,2009,36(6)：998-999.
[42]李元文,孙占学,张丰川,黎莲珺.中药苍柏湿毒清颗粒剂对解脲支原体体外作用的实验研究[J].中国性科学,2008,17(10)：10-12,17.
[43]沈黎明,喻林冲.解脲支原体对中药有效部位的药敏试验研究[J].华西药学杂志,2012,27(3)：294-295.
[44]顾红缨,罗晶.黄芩甙对解脲支原体体外抑制作用的实验研究[J].长春中医学院学报,2005,21(4)：44.
[45]李宏宇,汪军,李艳,等.中药制剂对解脲支原体的体外抑制作用实验研究[J].中国妇幼保健,2009,24(35)：5059-5060.
[46]黎莲珺.不同中药组方对解脲支原体体外抑制作用的实验研究[D].北京：北京中医药大学,2009.
[47]许庆瑞,吴秉纯,王伟明.抗解脲胶囊体外抗解脲支原体的实验研究[J].中国民族民间医药,2012,(13)：41,43.
[48]刘弘,赵红,苑贺英等.中药复方对解脲支原体感染小鼠T细胞亚群和细胞因子的影响[J].中国中医急症,2011,20(6)：917-919.
[49]许庆瑞,吴秉纯,王伟明.抗解脲胶囊对解脲支原体感染大鼠血清IL-8表达水平的影响[J].黑龙江中医药,2012(3)：53-54.
[50]苑贺英.妇科Ⅱ号方治疗雌性小鼠生殖道解脲支原体感染的实验研究[D].北京：北京中医药大学,2011.
[1]Thorsten V, RaIf O, Brigitte P. Ureaplasma urealyt icum harmless Commensal or underestimated enemy of human reproduction?[J]. Arch Gynecol Obstet,2005,273(3):133-139.
[2]Kong FR, Ma ZF, James G, etal.Species identification and subtyping of Ureaplasna parvum and Ureaplasma urcalyticun Using PCR-based assays[J], J Cllin Micrpbiol,2000,38(3):1175-1179.
[3]高玉红,张桂前,余泽芬.解脲支原体基因分型研究进展[J].云南大学学报(自然科学版),2011,33(S1)：330-332.
[4]刘朝晖,张淑增,任翊.解脲支原体在正常人群宫颈的存在情况及分群分型[J].中国实用妇科与产科杂志,2003,19(3)：161-163.
[5]郭兰’.解脲支原体致病机制研究进展[J].国外医学妇产科分册,2007,34(4)：22-24.
[6]张帝开,李秀云,覃春容,等.健康妇女下生殖道解脲脲原体及其分群分型研究[J].中国微生态杂志,2007,19(3)：288-292.
[7]郭兰.解脲支原体致病机制研究进展[J].国外医学妇产科分册,2007,34(4)：22-24.
[8]刘淑荣,张洪文.解脲支原体致病性与治疗决策[J].医学与哲学(临床决策论坛版),2009,30(10)：6-8.
[9]Rar VA, Maksimova TG, Trukhina AV, et al. Level of colonization by ureaplasma Urealyticum of definite biovars in a group of women with different clinical symptoms[J]. Zhmikrobiol Immunobiol,2004,8 (4):12-17.
[10]刘朝晖,张淑增,任翊.解脲支原体在正常人群宫颈的存在情况及分群分型.中国实用妇科与产科杂志,2003,19(3)：161-163.
[11]张洪文,陈琳,王新,等.解脲脲原体生物一群的耐药性研究[J].中国医师杂志,2007,9(5)：614-616.
[12]赵桦,童晓文,叶元康.解脲脲原体感染与女性生殖系统疾病的关系[J].世界感染杂志,2008,8(3)：230-232.
[13]Ekimov AN, Zagrebina OS, Kisina VI, et al. A method of genotyping clinical isolates of Ureaplasma Urealyticum biovar parvol[J].Mol Gel Microbiol Virusol,2001, (1):28-32.
[14]徐小平,李卓成,艾辉,等.解脲支原体分群分型在妇女非淋菌性尿道炎诊断中的应用[J].中国现代医学杂志,2007,171(21)：2647-2650.
[15]Kim II, Kim G, Eomero R, et al.Biovar diversity of Ureaplasma urealyticum in amniotic fluid: distribution, intrauterine inflammatory response and pregnancy outcoms[J]. J Perinat Med,2003,31(2):146-152.
[16]周丽萍,周洁,徐肖文.解脲脲原体血清型别与宫内感染的关系[J].中华医学检验杂志,1999,22(3).149-151.
[17]罗琼,李杰虹,缪宝琴,等.孕妇感染解脲支原体的数量及血清型与自然流产的关系[J].广东医学,2006,27(10)：1566.
[18]张帝开,李秀云,覃春容,等.健康妇女下生殖道解脲脲原体及其分群分型研究[J].中国微生态学杂志,2007,19(3)：288-292.
[19]曹玉璞,叶元康.支原体与支原体病[M].北京：人民卫生出版社,2000：80-84,121-129.
[20]旷思思,张洪文,吴献青.解脲支原体的致病性与Toll样受体[J].国际妇产科学杂志,2011,38(6)：506-504.
[21]Fernandez-Molina C, Latino MA, Zamora-Martinez Y,et al. Desarrollo de un metodo de PCR-multiple para la identif icacion de Ureaplasma parvum y Ureaplasma urealyticum[Development of a multiple PCR method for the identification of Ureaplasma parvum and Ureaplasma urealyticum [J].Rev Argent Microbiol,2003,35(3):138-142.
[22]Aujard Y, Maury L, Doit C, etal.UreaPlasma urealyticum, MycoPlasma hominis et Pathologies neonatales:Donnecs Personnelles et revue de lalitterature[UreaPlasma urealyticum and MycoPlasma hominis infections in newborns:personal data and review of the literature]. Arch Pediatr,2005, 12(Suppll):S12-S18.
[23]刘银秀,周聪云.560例不孕症妇女解脲支原体感染及耐药性分析[J].海峡药学,2010,22(9)：151-152.
[24]刘秀卿,张镇松.2057例阴道炎患者解脲支原体培养及耐药性分析[J].河北医学,2010,16(2)：193-195.
[25]刘菊珍,肖增璜,叶仲毅.泌尿生殖道支原体感染及耐药性分析[J].暨南大学学报(自然科学与医学版),2010,31(04)：418-420.
[26]Chen FJ, Lo IIJ. Molecular mechanisms of fluoroquinolone resistance[J]. J Microbiol Immunol Infect,2003,36(1):1-9.
[27]Xie X,Zhang J. Trends in the rates of resistance of ureaplasma urealyticum to antibiotics and identification of the mutation site in the quinolone resistance-determining region in Chinese patients[J]. FEMS Microbiol Lett,2006,259:181-186.
[28]Beeton ML, Chalker VJ, Kotecha S, et al. Comparison of full gyrA, gyrB, parC and parE gene sequences between all ureaplasma parvum and ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism[J]. J Antimicrob Chemother,2009,64(3):529-538.
[29]王春燕,杜江,吴森林,孙爱华.gyrA和parC基因突变与解脲支原体喹诺酮类药物耐药相关性研究[J].医学研究杂志,2012,41(10).63-66.
[30]Zhang W, Wu Y, Yin W, et al.Study of isolation of fluoroquinolone-resistant ureaplasma urealyticum and identification of mutant sites[J].Chin Med J,2002,115(10):1573-1575.
[31]刘长德,张艳,殷敏,等.超高倍显微诊断仪在泌尿生殖道支原体衣原体快速检查中的临床应用[J].中国实验诊断学,2008,11(11)：1433-1434.
[32]刘淑贤,贾向新,张辉,等.超高倍显微镜在泌尿生殖道支原体衣原体感染检测中应用[J].中国厂矿医学,2008,2(21)：20-21.
[33]吴全裕,谢正慧,吴勇,等.超高倍显微镜法和培养法检测阴道分泌物支原体结果比较[J].国际检验医学杂志,2013,34(1)：83,95.
[34]唐盛,林恒先,单万水.免疫荧光法检测解脲支原体的方法建立及临床应用评价[C].2010 First International Conference on Cellular,Molecular Biology, Biophysics and Bioengineering(CMBB).中国黑龙江齐齐哈尔:International Science and Engineering Center,Hong Kong. Wuhan Institute of Technology, China.2010:77-80.
[35]唐娟.FQ-PCR和液体培养法两种方法联合检测解脲支原体的临床意义[J].中国优生与遗传杂志,2010,18(1)：30、35.
[36]廖启洪,梁志东,孟晓.FQ-PCR检测不孕妇女沙眼衣原体和解脲支原体研究[J].中国优生与遗传杂志,2006,14(5)：36-38.
[37]吴晓红.两种方法检验解脲支原体的结果比较[J].江苏大学学报,2005,15(1)：71-72.
[38]肖文正.连接酶链反应(LCR)与聚合酶链反应(PCR)检测解脲支原体的比较[J].求医问药,2011,9(6)：116.
[39]邓昆,王丰,王珏,等.表面等离子体共振生物传感器快速检测解脲脲支原体的研究[J].中华医院感染学杂志,2011,21(10)：1968-1970.
[40]其木格,蒋法兴,苏晓红.支原体与女性生殖道感染的研究进展[J].国际皮肤性病学杂志.2007,33(2)：116-118.
[41]叶南圆,于红,王蓓.妇女生殖道感染患者支原体感染状况及其影响因素分析[J].现代预防医学,2008,35(18)：3520-3522.
[42]刘弘.妇科Ⅰ号方治疗盆腔炎性疾病病理及免疫机制初探[D].北京：北京中医药大学,2011.
[43]林森,葛少红,夏菲,陈小平.2004-2007年泌尿生殖道支原体感染率及耐药分析[J].检验医学与临床,2008,5(20)：1229-1230.
[44]张慧珠.285例妊娠妇女生殖道感染调查分析[J].中国优生与遗传杂志,2005,13(7)：82-83.
[45]房艳春,郭兆旭.孕妇生殖道感染[J].临床分析医护论坛,2009,6(25)：166-167.
[46]李妮.支原体、衣原体感染对不孕妇女生殖健康的影响(附298例临床分析)[J].中国妇幼保健,2008,23(34)：4874-4875.
[47]罗丽兰.不孕与不育[M].第1版.人民卫生出版社,1999.
[48]金春子,邵明明,马晓旗,等.西安地区男女不孕症与支原体感染的相关性研究.中国优生与遗传杂志,2006,14(1)：107、104.
[49]周静,张文森,郑飞云.输卵管性不孕与女性生殖道解脲支原体及沙眼衣原体感染的关系.中国妇幼保健,2008,23(34)：4875-4876.
[1]Furr PM,Taylor-robinson.D. The establishment and persistence of Ureaplasma urealyticum in oestradiol-treated femlale mice [J].Med Microbiol,1989,29 (2):111-114.
[2]杨建宏,王荣,王伟明,吴秉纯.解脲支原体感染非淋菌性尿道炎大鼠模型建立及评价[J].中药药理与临床,2008,24(5)：77-79.
[3]胡海翔,王喆,蔡庆,梁孟如.中药对解脲支原体感染大鼠睾丸形态学的影响[J].中国中医基础医学杂志,2001,7(1)：39-41.
[4]毛武塬.知柏地黄汤对解脲脲原体感染大鼠生精细胞促凋亡基因BAX、BAK干预作用的实验研究[D].湖南：湖南中医药大学,2010.
[5]Yoder BA. Effects of Antenatal Colonization with Ureaplasma urealyticum on Pulmonary Disease in the Immature Baboon[J]. PediatrRes,2003,54(6):797-807.
[6]张帝开,贾继辉,邝健全.解脲支原体对兔输卵管黏膜上皮细胞致病性研究[J].中国微生物学杂志,2003,15(5)：317.
[7]Taylor Robinson D, Furr PM. Observations on experimental colonisation of mice by ureaplasmas of human origin[J]. Med Microbiol,2002,51:866-870.
[8]苑贺英.妇科Ⅱ号方治疗雌性小鼠生殖道解脲支原体感染的实验研究[D].北京：北京中医药大学,2011.
[9]孙源梅,李元文,张颖纯,等.解脲支原体造模问题探讨[J].中国性科学,2012,21(3)：24-25.
[10]Abele-Horn M, Genzel-Boroviczeny 0, Uhlig T, et, al. Ureaplasma urealyticum colonization and bronchopulmonary dysplasia: a comparative prospective muticentre study[J]. Eur J Pediatr,1998,157:1004-1011.
[11]Rudd PT, Cassell GH, Waites KB, Davis Jk, Duffy LB. U reaplasma urealyticum pneumonia:experimental production and demonstration of age-related susceptibility[J]. Inlect Immun,1989,57(3):9119-9125.
[12]Viscardi RM, Kaplan J. Characterization of a MurineModel of Ureaplasma urealyticum Pneumonia[J].Infect Immun,2002,70:5721-5729.
[13]Benstein BD. Crouse DT. Shanklin DR. Ourth DD. Ureaplasma in lung. I. Localization by in situ hybridization in a mouse model [J]. Exp Mol Pathol,2003,75(2):165-170.
[14]Kotecha S, Hodge R, Schaber JA, Miralles R, Sliverman M, Grant WD. Pulmonary Ureaplasma urealyticum is associated with the development of acute lung inflammation and chronic lung disease in preterm infants[J].Pediatr Res,2004,55(1):61-68.
[15]周丽萍,陈韶,杨舟钻,等.解脲脲原体小鼠宫内感染的实验研究[J].中国人兽共患病杂志.1999,15：49-51.
[16]Yodei BA. Eff(?)ts of Antenatal Colonization with Ureaplasma urealyticum on Pulmonary Disease in the Immature Baboon[J]. PediatrRes,2003,54 (6):797-807.
[17]Shkampeta MM,Govorun VM. Experimental Mycoplasma hominis Infection of the Genital Tract in BALB/c Mice[J]. Immunology and microbiology,2004,1:53-56.
[18]李文瑾,胡国华.小鼠生殖道解脲支原体感染模型的建立(c).中华中医药学会全国第四次中医妇科学术研讨会论文汇编,2004.
[19]徐晨,孙广芳,王一飞.溶脲脲原体感染动物模型的建立——在泌尿生殖系中的分布[J].生殖医学杂志1994,3：228-231.
[20]杨建宏,张俊威,吴秉纯.解脲栓对解脲支原体感染大鼠免疫功能影响的研究[J].中药药理与临床,2008,24(1)：57-59.
[21]韩延华,王银凤,宋秀珍,辛雪艳.消抗灵Ⅱ号治疗解脲支原体感染小鼠的有效性研究[J].辽宁中医杂志,2008,35(4)：629.
[22]韩延华,辛雪艳.消抗灵Ⅱ号对小鼠解脲支原体感染及感染后血清中干扰素-Y的影响[J].世界中西医结合杂志,2008,3(2)：83-85.
[23]韩延华,于晨芳,韩延博.消抗灵Ⅱ号对小鼠解脲支原体感染及感染后血清中TNF-α的影响[J].世界中西医结合杂志,2008,3(3)：134-136.
[24]张连娣,蔡宝宏,梁学林,等.小鼠生殖道解脲支原体感染动物模型的建立与形态学研究.辽宁中医药大学学报[J].2009,11(2)：163-164.
[25]纪榕荣.不同浓度解脲支原体血清型1在兔模型中的致病性研究[D].湖南：中南大学,2009.
[26]刘淑荣.解腮支原体血清型3和8在母兔生殖道中的致病性研究[D].湖南：中南大学,2011.
[27]吴向军,袁杰利,梁红春,等.乳酸杆菌细胞裂解物对家兔实验性阴道炎的治疗作用[J].中国微生态学杂志,2007,19(6)：507-511.
[28]Furr PM, Taylor-robinson D. Factors iinfluenceing the ability of different mycoplasmas to colonize the genital tract of hormone-treated female mice[J]. EXP Pathol 1993,74(1):97-101.
[1]曹玉璞,叶元康.支原体与支原体病[M].北京：人民卫生出版社,2000：80-84,121-129.
[2]李元文,孙占学,张丰川,黎莲珺.中药苍柏湿毒清颗粒剂对解脲支原体体外作用的实验研究.中国性科学,2008,17(10)：10-12、17.
[3]郑筱萸,中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：1、24.
[4]王净净,中医临床病证诊断疗效标准[M].长沙：湖南科技出版社,1994：55、291.
[1]Kong FR,Ma ZF,James G,et,al. Species identification and subtyping of Ureaplasna parvum and Ureaplasma urcalyticun Using PCR-based assays[J].J Cllin Micrpbiol,2000,38 (3):1175-1179.
[2]高玉红,张桂前,余泽芬.解脲支原体基因分型研究进展[J].云南大学学报(自然科学版),2011,33(S1)：330-332.
[3]曹玉璞,叶元康.支原体与支原体病[M].北京：人民卫生出版社,2000：80-84,121-129.
[4]王勇,韩晓冬,精浆免疫抑制因子与解脲支原体感染[J].中国公共卫生,2004,20(3)：279-280.
[5]崔松伟.支原体培养与药敏试验[J].中国热带医学,2006,6(12)：2227、2271.
[6]刘银秀,周聪云.560例不孕症妇女解脲支原体感染及耐药性分析[J].海峡药学,2010,22(9)：151-152.
[7]刘秀卿,张镇松.2057例阴道炎患者解脲支原体培养及耐药性分析[J].河北医学,2010,16(2)：193-195.
[8]旷思思,张洪文,吴献青.解脲支原体的致病性与Toll样受体[J].国际妇产科学杂志,2011,38(6)：500-504.
[9]Aujard Y, Maury L, Doit C, etal.UreaPlasma urealyticum MycoPlasma hominis et Pathologies neonatales:Donnees Personnelles et revue de lalitterature[UreaPlasma urealyticum and MycoPlasma hominis infections in newborns:personal data and review of the literature].Arch Pediatr,2005,12 (Suppll):S12-S18.
[10]杜久伟,许克义,陈天义,等.女性不孕患者解脲支原体感染与外周血T细胞亚群水平检测[J].中国煤炭工业医学杂志,2006,9(4)：345.
[11]刘保国,李志英,盖自宽.六味地黄丸对解脲支原体感染后精液质量及IL-1β、IL-8的影响[J].中国中医基础医学杂志,2011,(8)：895-896.
[12]李元文,孙占学.苍柏湿毒清治疗解脲支原体性尿道(宫颈)炎的临床 疗效观察[J].中国性科学,2008,17(5)：10.
[13]李元文,孙占学,张丰川,黎莲珺.中药苍柏湿毒清颗粒剂对解脲支原体体外作用的实验研究.中国性科学,2008,17(10)：10-12、17.
[14]蔡玲玲,李元文,张丰川.苍柏湿毒清颗粒使支原体耐药菌株产生敏感化趋势以及与白介素IL-2、IL-12的相关性研究[J].中华中医药杂志(原中国医药学报),2012,27(1)：172-175.
[15]刘梅玲.白三烯在炎症中的作用[J].皖南医学院学报,1988,1(7)：69-72.
[16]何爽,代艳,杜华.白三烯研究进展[J].中国临床新医学.2009,2(5)：455-457.
[17]马雪云,韩建秋,牛钟相,等.补体C3b肽段的免疫功能[J].动物医学进展.2005,26(6)：105-107.
[18]龚非力.医学免疫学[M].北京：科学出版社,2000：155-156.
[19]魏民.病理学[M].上海：上海科学技术出版社,1995：72-75.
[20]黄峰,刘凤莉,寇小妮,等.加味寿胎胶囊对乙肝免疫耐受患者血清IL-2、IFN-γ的影响[J].陕西中医学院学报,2011,(5)：49-50.
[21]高学敏,钟赣生.临床中药学[M].石家庄：河北科学技术出版社,第1版,2006：429.
[22]向亚平,胡伟才,杨志波.芪苓解浊颗粒剂抗解脲支原体的体外实验研究[J].中国麻风皮肤病杂志,2005,21(7)：535.
[23]Furr PM,Taylor-robinson.D.The establishment and persistence of Ureaplasma urealyticum in oestradiol-treated female mice[J].Med Microbiol,1989,29(2):111-114.
[2]薛连才.黄连解毒汤加味在解脲支原体感染患者中的应用[J].中国药物与临床,2012,12(增刊)：81.
[3]雷林,赵荣.中药内服外用治疗女性解脲支原体、沙眼衣原体感染36例疗效观察[J].天津中医药,2007,24(1)：32.
[4]徐东杰.康乐宁治疗女性泌尿生殖道解脉支原体感染的临床观察及研究[D].长春：长春中医药大学,2007.
[5]杨小芳.中西医联合治疗支原体衣原体生殖道感染[J].中华中医药学刊,2007,25(4)：850-851.
[6]陈启显,陈劝显.中西医结合治疗非淋菌性尿道炎36例疗效观察[J].实用中西医结合临床,2006,6(1)：35.
[7]邢燕军.复方利康液外用治疗解脲支原体性阴道炎的临床疗效观察[J].中国实验方剂学杂志,2003,9(4)：64.
[8]冯光荣,张娜.加味五味消毒饮联合阿奇霉素治疗解脲支原体阳性宫颈炎30例疗效观察[J].河南中医,2008,28(9)：46-47.
[9]夏如意,谈珍瑜,刘文娥.盆炎丸治疗多重耐药解脲支原体感染的临床观察[J].湖南中医药大学学报,2012,32(3)：53-55,67.
[10]宋春花,常欣峰,韩立民.带下病中医辨证分型与解脲支原体感染的关系[J].赣南医学院学报,2010,30(2)：260.
[11]陈旭.梁学林教授治疗耐药性解脲支原体感染及继发不孕症经验[J].中华中医药学刊,2007,25(6)：1116-1117.
[12]韦红,陈琢,徐萍.洁泽Ⅰ号抗解脲支原体药效实验及其对解脲支原体宫颈炎的治疗作用[J].华中科技大学学报(医学版),2007,36(1)：87-90.
[13]李元文,孙占学,张丰川.中药苍柏湿毒清颗粒剂对解脲支原体体外作用的实验研究[J].中国性科学,2008,17(10)：10-12、17.
[14]陈少芳,叶敦敏.中西医结合治疗女性解脲支原体生殖道感染50例[J].新中医,2006,38(8)：78.
[15]任光荣.《傅青主女科》带下五方的学习应用体会[J].甘肃中医,2008,21(11)：2-4.
[16]张志礼.中西医结合皮肤性病学[M].北京：人民卫生出版社,2000：380-383.
[17]吴英男.辨证治疗非淋菌性尿道炎106例[J].实用中医内科杂志,2002,16(1)：43.
[18]丁原全,马乾章.中医辨证与支原体感染浅析[J].辽宁中医杂志,2002,29(12)：716.
[19]李元文,张丰川.性病防治420问[M].北京：中国中医药出版社,2005：159-161.
[20]陈旭.梁学林教授治疗耐药性解脲支原体感染及继发不孕症经验[J].中华中医药学刊,2007,25(6)：1115-1116.
[21]樊庆华,谢争,丁辉.中药用于泌尿生殖系统支原体感染并抗生素耐药病例疗效评估[J].中国妇幼保健,2006,21(5)：710-711.
[22]孙跃农,胡莺,林雯.中医药治疗解脉支原体感染所致滑胎48例临床观察[J].云南中医中药杂志,2007,28(11)：17-18.
[23]毛惠,戴晓蓉,詹平.中药内服外洗治疗妊娠中晚期解脲支原体感染60例[J].中国中西医结合杂志,2006,07(5)：89.
[24]张立春,田成海,梁丽丽.黄连粉治疗解脲支原体阴道炎60例疗效观察[J].长春中医药大学学报,2011,27(6)：1024.
[25]邢燕军.复方利康液外用治疗解脲支原体性阴道炎的临床疗效观察[J].中国实验方剂学杂志,2003,9(4)：64.
[26]田虹利,冯洪声,张淑杰.黄鹤止痒方治疗支原体阴道炎80例[J].陕西中医,2009,30(11)：1462.
[27]李海,邱曙光.阴道微波联合中药冲洗治疗女性解脉支原体感染80例临床观察[J].中国性科学,2008,17(9)：21-22.
[28]梁文丽,杨志新,谢爱香.联合用药治疗女性生殖道支原体感染30例[J].中国中医药现代远程教育,2011,10(01)：141-142.
[29]李艳莎,张新.中西医结合治疗泌尿生殖道支原体感染的临床用药体会[J].中医临床研究,2012,4(12)：11-12.
[30]石慧,谢靳.胆泻肝汤联合阿奇霉素阴道给药治疗女性生殖道解脲支原体感染[J].中西医结合研究,2012,4(1)：1-3.
[31]王雪鹤,樊希芬,郝建波.夕腥草外用联合克拉霉素治疗生殖道解脲支原体感染 138例[J].青岛医药卫生,2005,37(3)：180.
[32]王薇华,刘格,叶花.中西医结合外治法治疗耐药性解脲支原体感染33例临床观察[J].中医药导报,2012,18(7)：41-42.
[33]张颖纯.外用加味四黄洗剂治疗女性解脲支原体感染阴道(宫颈)炎的临床研究[D].北京：北京中医药大学,2012.
[34]赵剑英.中西医结合治疗解脉支原体泌尿生殖道感染[J].浙江中西医结合杂志,2007,17(5)：308-309.
[35]朱习平,高思娥,钱纪银.中西医联合治疗女性生殖道解脉支原体感染的疗效观察[J].中国医药指南,2007,5(10)：171-172.
[36]杨小芳.中西医联合治疗支原体衣原体生殖道感染[J].中华中医药学刊,2007,25(4)：850-851.
[37]邓卫红.中西医结合治疗支原体、衣原体生殖道感染疗效观察[J].中国中医急症,2009,18(3)：372-373.
[38]吴庆四,朱长太,徐东芳等.中药对解脲支原体临床分离株的体外抑制试验研究[J].安徽医药,2006,10(5)：332-333.
[39]董海艳,周丽萍,王乐丹.3味中药对解脲支原体体外抑制作用的实验研究[J].现代中西医结合杂志,2004,13(21)：2824、2827.
[40]廖镜云,郭汉香.解脲支原体中药药敏试验[J].江西中医学院学报,2006,18(3)：56-57.
[41]田正阳,丁原全,梁学林.中药抗解脲支原体的药敏试验[J].辽宁中医杂志,2009,36(6)：998-999.
[42]李元文,孙占学,张丰川,黎莲珺.中药苍柏湿毒清颗粒剂对解脲支原体体外作用的实验研究[J].中国性科学,2008,17(10)：10-12,17.
[43]沈黎明,喻林冲.解脲支原体对中药有效部位的药敏试验研究[J].华西药学杂志,2012,27(3)：294-295.
[44]顾红缨,罗晶.黄芩甙对解脲支原体体外抑制作用的实验研究[J].长春中医学院学报,2005,21(4)：44.
[45]李宏宇,汪军,李艳,等.中药制剂对解脲支原体的体外抑制作用实验研究[J].中国妇幼保健,2009,24(35)：5059-5060.
[46]黎莲珺.不同中药组方对解脲支原体体外抑制作用的实验研究[D].北京：北京中医药大学,2009.
[47]许庆瑞,吴秉纯,王伟明.抗解脲胶囊体外抗解脲支原体的实验研究[J].中国民族民间医药,2012,(13)：41,43.
[48]刘弘,赵红,苑贺英等.中药复方对解脲支原体感染小鼠T细胞亚群和细胞因子的影响[J].中国中医急症,2011,20(6)：917-919.
[49]许庆瑞,吴秉纯,王伟明.抗解脲胶囊对解脲支原体感染大鼠血清IL-8表达水平的影响[J].黑龙江中医药,2012(3)：53-54.
[50]苑贺英.妇科Ⅱ号方治疗雌性小鼠生殖道解脲支原体感染的实验研究[D].北京：北京中医药大学,2011.
[1]Thorsten V, RaIf O, Brigitte P. Ureaplasma urealyt icum harmless Commensal or underestimated enemy of human reproduction?[J]. Arch Gynecol Obstet,2005,273(3):133-139.
[2]Kong FR, Ma ZF, James G, etal.Species identification and subtyping of Ureaplasna parvum and Ureaplasma urcalyticun Using PCR-based assays[J], J Cllin Micrpbiol,2000,38(3):1175-1179.
[3]高玉红,张桂前,余泽芬.解脲支原体基因分型研究进展[J].云南大学学报(自然科学版),2011,33(S1)：330-332.
[4]刘朝晖,张淑增,任翊.解脲支原体在正常人群宫颈的存在情况及分群分型[J].中国实用妇科与产科杂志,2003,19(3)：161-163.
[5]郭兰’.解脲支原体致病机制研究进展[J].国外医学妇产科分册,2007,34(4)：22-24.
[6]张帝开,李秀云,覃春容,等.健康妇女下生殖道解脲脲原体及其分群分型研究[J].中国微生态杂志,2007,19(3)：288-292.
[7]郭兰.解脲支原体致病机制研究进展[J].国外医学妇产科分册,2007,34(4)：22-24.
[8]刘淑荣,张洪文.解脲支原体致病性与治疗决策[J].医学与哲学(临床决策论坛版),2009,30(10)：6-8.
[9]Rar VA, Maksimova TG, Trukhina AV, et al. Level of colonization by ureaplasma Urealyticum of definite biovars in a group of women with different clinical symptoms[J]. Zhmikrobiol Immunobiol,2004,8 (4):12-17.
[10]刘朝晖,张淑增,任翊.解脲支原体在正常人群宫颈的存在情况及分群分型.中国实用妇科与产科杂志,2003,19(3)：161-163.
[11]张洪文,陈琳,王新,等.解脲脲原体生物一群的耐药性研究[J].中国医师杂志,2007,9(5)：614-616.
[12]赵桦,童晓文,叶元康.解脲脲原体感染与女性生殖系统疾病的关系[J].世界感染杂志,2008,8(3)：230-232.
[13]Ekimov AN, Zagrebina OS, Kisina VI, et al. A method of genotyping clinical isolates of Ureaplasma Urealyticum biovar parvol[J].Mol Gel Microbiol Virusol,2001, (1):28-32.
[14]徐小平,李卓成,艾辉,等.解脲支原体分群分型在妇女非淋菌性尿道炎诊断中的应用[J].中国现代医学杂志,2007,171(21)：2647-2650.
[15]Kim II, Kim G, Eomero R, et al.Biovar diversity of Ureaplasma urealyticum in amniotic fluid: distribution, intrauterine inflammatory response and pregnancy outcoms[J]. J Perinat Med,2003,31(2):146-152.
[16]周丽萍,周洁,徐肖文.解脲脲原体血清型别与宫内感染的关系[J].中华医学检验杂志,1999,22(3).149-151.
[17]罗琼,李杰虹,缪宝琴,等.孕妇感染解脲支原体的数量及血清型与自然流产的关系[J].广东医学,2006,27(10)：1566.
[18]张帝开,李秀云,覃春容,等.健康妇女下生殖道解脲脲原体及其分群分型研究[J].中国微生态学杂志,2007,19(3)：288-292.
[19]曹玉璞,叶元康.支原体与支原体病[M].北京：人民卫生出版社,2000：80-84,121-129.
[20]旷思思,张洪文,吴献青.解脲支原体的致病性与Toll样受体[J].国际妇产科学杂志,2011,38(6)：506-504.
[21]Fernandez-Molina C, Latino MA, Zamora-Martinez Y,et al. Desarrollo de un metodo de PCR-multiple para la identif icacion de Ureaplasma parvum y Ureaplasma urealyticum[Development of a multiple PCR method for the identification of Ureaplasma parvum and Ureaplasma urealyticum [J].Rev Argent Microbiol,2003,35(3):138-142.
[22]Aujard Y, Maury L, Doit C, etal.UreaPlasma urealyticum, MycoPlasma hominis et Pathologies neonatales:Donnecs Personnelles et revue de lalitterature[UreaPlasma urealyticum and MycoPlasma hominis infections in newborns:personal data and review of the literature]. Arch Pediatr,2005, 12(Suppll):S12-S18.
[23]刘银秀,周聪云.560例不孕症妇女解脲支原体感染及耐药性分析[J].海峡药学,2010,22(9)：151-152.
[24]刘秀卿,张镇松.2057例阴道炎患者解脲支原体培养及耐药性分析[J].河北医学,2010,16(2)：193-195.
[25]刘菊珍,肖增璜,叶仲毅.泌尿生殖道支原体感染及耐药性分析[J].暨南大学学报(自然科学与医学版),2010,31(04)：418-420.
[26]Chen FJ, Lo IIJ. Molecular mechanisms of fluoroquinolone resistance[J]. J Microbiol Immunol Infect,2003,36(1):1-9.
[27]Xie X,Zhang J. Trends in the rates of resistance of ureaplasma urealyticum to antibiotics and identification of the mutation site in the quinolone resistance-determining region in Chinese patients[J]. FEMS Microbiol Lett,2006,259:181-186.
[28]Beeton ML, Chalker VJ, Kotecha S, et al. Comparison of full gyrA, gyrB, parC and parE gene sequences between all ureaplasma parvum and ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism[J]. J Antimicrob Chemother,2009,64(3):529-538.
[29]王春燕,杜江,吴森林,孙爱华.gyrA和parC基因突变与解脲支原体喹诺酮类药物耐药相关性研究[J].医学研究杂志,2012,41(10).63-66.
[30]Zhang W, Wu Y, Yin W, et al.Study of isolation of fluoroquinolone-resistant ureaplasma urealyticum and identification of mutant sites[J].Chin Med J,2002,115(10):1573-1575.
[31]刘长德,张艳,殷敏,等.超高倍显微诊断仪在泌尿生殖道支原体衣原体快速检查中的临床应用[J].中国实验诊断学,2008,11(11)：1433-1434.
[32]刘淑贤,贾向新,张辉,等.超高倍显微镜在泌尿生殖道支原体衣原体感染检测中应用[J].中国厂矿医学,2008,2(21)：20-21.
[33]吴全裕,谢正慧,吴勇,等.超高倍显微镜法和培养法检测阴道分泌物支原体结果比较[J].国际检验医学杂志,2013,34(1)：83,95.
[34]唐盛,林恒先,单万水.免疫荧光法检测解脲支原体的方法建立及临床应用评价[C].2010 First International Conference on Cellular,Molecular Biology, Biophysics and Bioengineering(CMBB).中国黑龙江齐齐哈尔:International Science and Engineering Center,Hong Kong. Wuhan Institute of Technology, China.2010:77-80.
[35]唐娟.FQ-PCR和液体培养法两种方法联合检测解脲支原体的临床意义[J].中国优生与遗传杂志,2010,18(1)：30、35.
[36]廖启洪,梁志东,孟晓.FQ-PCR检测不孕妇女沙眼衣原体和解脲支原体研究[J].中国优生与遗传杂志,2006,14(5)：36-38.
[37]吴晓红.两种方法检验解脲支原体的结果比较[J].江苏大学学报,2005,15(1)：71-72.
[38]肖文正.连接酶链反应(LCR)与聚合酶链反应(PCR)检测解脲支原体的比较[J].求医问药,2011,9(6)：116.
[39]邓昆,王丰,王珏,等.表面等离子体共振生物传感器快速检测解脲脲支原体的研究[J].中华医院感染学杂志,2011,21(10)：1968-1970.
[40]其木格,蒋法兴,苏晓红.支原体与女性生殖道感染的研究进展[J].国际皮肤性病学杂志.2007,33(2)：116-118.
[41]叶南圆,于红,王蓓.妇女生殖道感染患者支原体感染状况及其影响因素分析[J].现代预防医学,2008,35(18)：3520-3522.
[42]刘弘.妇科Ⅰ号方治疗盆腔炎性疾病病理及免疫机制初探[D].北京：北京中医药大学,2011.
[43]林森,葛少红,夏菲,陈小平.2004-2007年泌尿生殖道支原体感染率及耐药分析[J].检验医学与临床,2008,5(20)：1229-1230.
[44]张慧珠.285例妊娠妇女生殖道感染调查分析[J].中国优生与遗传杂志,2005,13(7)：82-83.
[45]房艳春,郭兆旭.孕妇生殖道感染[J].临床分析医护论坛,2009,6(25)：166-167.
[46]李妮.支原体、衣原体感染对不孕妇女生殖健康的影响(附298例临床分析)[J].中国妇幼保健,2008,23(34)：4874-4875.
[47]罗丽兰.不孕与不育[M].第1版.人民卫生出版社,1999.
[48]金春子,邵明明,马晓旗,等.西安地区男女不孕症与支原体感染的相关性研究.中国优生与遗传杂志,2006,14(1)：107、104.
[49]周静,张文森,郑飞云.输卵管性不孕与女性生殖道解脲支原体及沙眼衣原体感染的关系.中国妇幼保健,2008,23(34)：4875-4876.
[1]Furr PM,Taylor-robinson.D. The establishment and persistence of Ureaplasma urealyticum in oestradiol-treated femlale mice [J].Med Microbiol,1989,29 (2):111-114.
[2]杨建宏,王荣,王伟明,吴秉纯.解脲支原体感染非淋菌性尿道炎大鼠模型建立及评价[J].中药药理与临床,2008,24(5)：77-79.
[3]胡海翔,王喆,蔡庆,梁孟如.中药对解脲支原体感染大鼠睾丸形态学的影响[J].中国中医基础医学杂志,2001,7(1)：39-41.
[4]毛武塬.知柏地黄汤对解脲脲原体感染大鼠生精细胞促凋亡基因BAX、BAK干预作用的实验研究[D].湖南：湖南中医药大学,2010.
[5]Yoder BA. Effects of Antenatal Colonization with Ureaplasma urealyticum on Pulmonary Disease in the Immature Baboon[J]. PediatrRes,2003,54(6):797-807.
[6]张帝开,贾继辉,邝健全.解脲支原体对兔输卵管黏膜上皮细胞致病性研究[J].中国微生物学杂志,2003,15(5)：317.
[7]Taylor Robinson D, Furr PM. Observations on experimental colonisation of mice by ureaplasmas of human origin[J]. Med Microbiol,2002,51:866-870.
[8]苑贺英.妇科Ⅱ号方治疗雌性小鼠生殖道解脲支原体感染的实验研究[D].北京：北京中医药大学,2011.
[9]孙源梅,李元文,张颖纯,等.解脲支原体造模问题探讨[J].中国性科学,2012,21(3)：24-25.
[10]Abele-Horn M, Genzel-Boroviczeny 0, Uhlig T, et, al. Ureaplasma urealyticum colonization and bronchopulmonary dysplasia: a comparative prospective muticentre study[J]. Eur J Pediatr,1998,157:1004-1011.
[11]Rudd PT, Cassell GH, Waites KB, Davis Jk, Duffy LB. U reaplasma urealyticum pneumonia:experimental production and demonstration of age-related susceptibility[J]. Inlect Immun,1989,57(3):9119-9125.
[12]Viscardi RM, Kaplan J. Characterization of a MurineModel of Ureaplasma urealyticum Pneumonia[J].Infect Immun,2002,70:5721-5729.
[13]Benstein BD. Crouse DT. Shanklin DR. Ourth DD. Ureaplasma in lung. I. Localization by in situ hybridization in a mouse model [J]. Exp Mol Pathol,2003,75(2):165-170.
[14]Kotecha S, Hodge R, Schaber JA, Miralles R, Sliverman M, Grant WD. Pulmonary Ureaplasma urealyticum is associated with the development of acute lung inflammation and chronic lung disease in preterm infants[J].Pediatr Res,2004,55(1):61-68.
[15]周丽萍,陈韶,杨舟钻,等.解脲脲原体小鼠宫内感染的实验研究[J].中国人兽共患病杂志.1999,15：49-51.
[16]Yodei BA. Eff(?)ts of Antenatal Colonization with Ureaplasma urealyticum on Pulmonary Disease in the Immature Baboon[J]. PediatrRes,2003,54 (6):797-807.
[17]Shkampeta MM,Govorun VM. Experimental Mycoplasma hominis Infection of the Genital Tract in BALB/c Mice[J]. Immunology and microbiology,2004,1:53-56.
[18]李文瑾,胡国华.小鼠生殖道解脲支原体感染模型的建立(c).中华中医药学会全国第四次中医妇科学术研讨会论文汇编,2004.
[19]徐晨,孙广芳,王一飞.溶脲脲原体感染动物模型的建立——在泌尿生殖系中的分布[J].生殖医学杂志1994,3：228-231.
[20]杨建宏,张俊威,吴秉纯.解脲栓对解脲支原体感染大鼠免疫功能影响的研究[J].中药药理与临床,2008,24(1)：57-59.
[21]韩延华,王银凤,宋秀珍,辛雪艳.消抗灵Ⅱ号治疗解脲支原体感染小鼠的有效性研究[J].辽宁中医杂志,2008,35(4)：629.
[22]韩延华,辛雪艳.消抗灵Ⅱ号对小鼠解脲支原体感染及感染后血清中干扰素-Y的影响[J].世界中西医结合杂志,2008,3(2)：83-85.
[23]韩延华,于晨芳,韩延博.消抗灵Ⅱ号对小鼠解脲支原体感染及感染后血清中TNF-α的影响[J].世界中西医结合杂志,2008,3(3)：134-136.
[24]张连娣,蔡宝宏,梁学林,等.小鼠生殖道解脲支原体感染动物模型的建立与形态学研究.辽宁中医药大学学报[J].2009,11(2)：163-164.
[25]纪榕荣.不同浓度解脲支原体血清型1在兔模型中的致病性研究[D].湖南：中南大学,2009.
[26]刘淑荣.解腮支原体血清型3和8在母兔生殖道中的致病性研究[D].湖南：中南大学,2011.
[27]吴向军,袁杰利,梁红春,等.乳酸杆菌细胞裂解物对家兔实验性阴道炎的治疗作用[J].中国微生态学杂志,2007,19(6)：507-511.
[28]Furr PM, Taylor-robinson D. Factors iinfluenceing the ability of different mycoplasmas to colonize the genital tract of hormone-treated female mice[J]. EXP Pathol 1993,74(1):97-101.
[1]曹玉璞,叶元康.支原体与支原体病[M].北京：人民卫生出版社,2000：80-84,121-129.
[2]李元文,孙占学,张丰川,黎莲珺.中药苍柏湿毒清颗粒剂对解脲支原体体外作用的实验研究.中国性科学,2008,17(10)：10-12、17.
[3]郑筱萸,中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002：1、24.
[4]王净净,中医临床病证诊断疗效标准[M].长沙：湖南科技出版社,1994：55、291.
[1]Kong FR,Ma ZF,James G,et,al. Species identification and subtyping of Ureaplasna parvum and Ureaplasma urcalyticun Using PCR-based assays[J].J Cllin Micrpbiol,2000,38 (3):1175-1179.
[2]高玉红,张桂前,余泽芬.解脲支原体基因分型研究进展[J].云南大学学报(自然科学版),2011,33(S1)：330-332.
[3]曹玉璞,叶元康.支原体与支原体病[M].北京：人民卫生出版社,2000：80-84,121-129.
[4]王勇,韩晓冬,精浆免疫抑制因子与解脲支原体感染[J].中国公共卫生,2004,20(3)：279-280.
[5]崔松伟.支原体培养与药敏试验[J].中国热带医学,2006,6(12)：2227、2271.
[6]刘银秀,周聪云.560例不孕症妇女解脲支原体感染及耐药性分析[J].海峡药学,2010,22(9)：151-152.
[7]刘秀卿,张镇松.2057例阴道炎患者解脲支原体培养及耐药性分析[J].河北医学,2010,16(2)：193-195.
[8]旷思思,张洪文,吴献青.解脲支原体的致病性与Toll样受体[J].国际妇产科学杂志,2011,38(6)：500-504.
[9]Aujard Y, Maury L, Doit C, etal.UreaPlasma urealyticum MycoPlasma hominis et Pathologies neonatales:Donnees Personnelles et revue de lalitterature[UreaPlasma urealyticum and MycoPlasma hominis infections in newborns:personal data and review of the literature].Arch Pediatr,2005,12 (Suppll):S12-S18.
[10]杜久伟,许克义,陈天义,等.女性不孕患者解脲支原体感染与外周血T细胞亚群水平检测[J].中国煤炭工业医学杂志,2006,9(4)：345.
[11]刘保国,李志英,盖自宽.六味地黄丸对解脲支原体感染后精液质量及IL-1β、IL-8的影响[J].中国中医基础医学杂志,2011,(8)：895-896.
[12]李元文,孙占学.苍柏湿毒清治疗解脲支原体性尿道(宫颈)炎的临床 疗效观察[J].中国性科学,2008,17(5)：10.
[13]李元文,孙占学,张丰川,黎莲珺.中药苍柏湿毒清颗粒剂对解脲支原体体外作用的实验研究.中国性科学,2008,17(10)：10-12、17.
[14]蔡玲玲,李元文,张丰川.苍柏湿毒清颗粒使支原体耐药菌株产生敏感化趋势以及与白介素IL-2、IL-12的相关性研究[J].中华中医药杂志(原中国医药学报),2012,27(1)：172-175.
[15]刘梅玲.白三烯在炎症中的作用[J].皖南医学院学报,1988,1(7)：69-72.
[16]何爽,代艳,杜华.白三烯研究进展[J].中国临床新医学.2009,2(5)：455-457.
[17]马雪云,韩建秋,牛钟相,等.补体C3b肽段的免疫功能[J].动物医学进展.2005,26(6)：105-107.
[18]龚非力.医学免疫学[M].北京：科学出版社,2000：155-156.
[19]魏民.病理学[M].上海：上海科学技术出版社,1995：72-75.
[20]黄峰,刘凤莉,寇小妮,等.加味寿胎胶囊对乙肝免疫耐受患者血清IL-2、IFN-γ的影响[J].陕西中医学院学报,2011,(5)：49-50.
[21]高学敏,钟赣生.临床中药学[M].石家庄：河北科学技术出版社,第1版,2006：429.
[22]向亚平,胡伟才,杨志波.芪苓解浊颗粒剂抗解脲支原体的体外实验研究[J].中国麻风皮肤病杂志,2005,21(7)：535.
[23]Furr PM,Taylor-robinson.D.The establishment and persistence of Ureaplasma urealyticum in oestradiol-treated female mice[J].Med Microbiol,1989,29(2):111-114.